Document:

EX-10.11

 Exhibit 10.11 
  

 
 June 16, 2014 

D. Ryan Daws 
 c/o 

Concert Pharmaceuticals, Inc. 
 99 Hayden Avenue, Suite 500 

Lexington, MA 02421 
 Dear Mr. Daws: 

This agreement revises the terms of your continued employment as Chief Financial Officer of Concert Pharmaceuticals, Inc. (the
“Company” or “Concert” and, with you, the “Parties”) reporting to the Company’s Chief Executive Officer, effective as of June 10, 2014 (the “Effective
Date”). You agree to continue to perform the duties of your position and such other duties as the Company’s Board of Directors (the “Board”) may reasonably assign to you from time to time. 

At Concert you will develop strategies for company financing and represent the Company on financial and corporate strategy matters in dealings
with investors and analysts, including public offerings the Company may pursue. You will serve as a key advisor to the Chief Executive Officer and Board of Directors and assist with the development and execution of the overall strategy and direction
of the Company. Also, you will lead all financial operations of the company, including financial planning and budgeting, accounting and reporting, and investment management. In addition, as the Company may require, you will lead business development
activities in collaboration with Concert’s senior management team. 
 1. Salary. You will receive annualized base salary
of $308,000 per year (as in effect from the Effective Date), payable in accordance with the regular payroll practices of the Company and less applicable taxes and withholdings, as in effect from time to time. The base salary shall be subject to
increase from time to time by the Compensation Committee of the Board (the “Compensation Committee”) in its exclusive discretion. 

2. Bonus. During your employment, you are eligible for an annual discretionary performance bonus in addition to your base
salary. Bonus compensation in any year, if any, will be based on your performance and/or that of the Company, in accordance with a general bonus program to be established by the Board (and administered by the Compensation Committee) and will be
payable not later than two and one-half months following the calendar year, except as the bonus program may from time to time provide. 
 In
addition, the Company paid you a one-time signing bonus of ninety-seven thousand dollars ($97,000.00) in a lump sum. If your employment ends within the first 12 months after your date of employment because of your voluntary resignation (other than
on a resignation for Good Reason) or because the Company terminates your employment for Cause, you agree to reimburse Concert the ninety-seven thousand dollar signing bonus, net of any taxes the Company withheld on such bonus, within two months
following such termination. 

 3. Benefits; Vacation. You will be entitled to participate in all employee benefit
plans from time to time in effect for employees of the Company generally. Your participation will be subject to the terms of the applicable plan documents and generally applicable Company policies. Benefits are subject to change at any time at the
Company’s sole discretion. You will remain eligible to accrue three weeks paid vacation in each calendar year (or such greater amount as is generally made available in accordance with the Company’s policies from time to time in effect), in
addition to holidays observed by the Company. Vacation may be taken at such times and intervals as you shall determine, subject to the business needs of the Company, and otherwise shall be subject to the policies of the Company, as in effect from
time to time. You confirm that you have received the Option referenced in the January 16, 2014 version of this Agreement. 
 4.
Expense Reimbursement. The Company will pay or reimburse you for all and customary reasonable out-of-pocket business expenses incurred or paid by you in the performance of your duties and responsibilities for the Company, subject to
any maximum annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and documentation as the Company may specify. Any such reimbursement that would constitute nonqualified deferred compensation
subject to Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A” of the “Code”) shall be subject to the following additional rules: (i) no reimbursement of any such
expense shall affect your right to reimbursement of any other such expense in any other taxable year; (ii) reimbursement of the expense shall be made, if at all, not later than the end of the calendar year following the calendar year in which
the expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation or exchange for any other benefit. 

5. Confidentiality Agreement. You represent that you have complied and agree that you will continue to comply with the Employee
Confidentiality, Non-Competition, and Proprietary Information Agreement between the Company and you dated January 20, 2014 (the “Confidentiality Agreement”). It is understood and agreed that a breach by you of the
Confidentiality Agreement would be a material breach of this Agreement. 
 6. At-Will; Timing for Termination; Accrued
Benefits. This employment letter is not intended to create or constitute an employment agreement or contract (express or implied) between you and the Company for a fixed term. It is also important for you to understand that Massachusetts is
an “at will” employment state. This means that you will have the right to terminate your employment relationship with the Company at any time for any reason, although you are requested to give at least two weeks’ notice. Similarly,
the Company will have the right to terminate its employment relationship with you at any time for any reason. You may terminate your employment hereunder for Good Reason (as defined below) by providing notice to the Company of the condition giving
rise to the Good Reason no later than 30 days following the occurrence of the condition, by giving the Company 30 days to remedy the condition and by terminating employment for Good Reason within 30 days thereafter if the Company fails to remedy the
condition. Upon your termination, the Company will pay on the date of termination any base salary earned but not paid through the date of termination and pay for any vacation time accrued but not used to that date. In addition, the Company will pay
you any bonus that has been awarded to you and earned, but not yet paid on the termination of your employment (together with the preceding sentence, the “Accrued Benefits”). In the event of any termination of your

  
 2 

 
employment, other than a termination under Section 7 or as provided for COBRA under Section 7(c), the Company shall have no obligation to you under this Agreement other than with
respect to the Accrued Benefits. 
 7. Termination without Cause; Termination for Good Reason. 

(a) Severance Pay. A termination by you for Good Reason, or any termination of your employment by the Company
(other than for Cause, as defined below, death, or inability to perform as a result of physical or mental infirmity (“disability”)) shall entitle you to 12 months of severance pay (the “Severance Pay”)
and the other compensation provided in this section, as well as to the Accrued Benefits. The Severance Pay shall be calculated on the basis of your base salary as of the date the Company gives you notice of your termination and shall be exclusive of
any bonus or benefit payments. The Company will provide the Severance Pay in the form of salary continuation in accordance with the normal payroll practices of the Company, beginning with the Company’s next regular payroll period following the
Effective Release Date (as defined below), with the first payment including any amounts that would have been paid between the termination date and the Effective Release Date if the payments had commenced on the termination date and with the
remaining payments made proportionately over the remainder of the 12 month severance period. The receipt of any severance benefits provided for under this Section 7 or otherwise shall be dependent upon your delivery to the Company, within 60
days following the date of termination of employment, of an effective general release of claims in a form promptly provided by the Company; provided, however, that if the last day of the 60 day period falls in the calendar year following the year of
your date of termination, the severance payments shall be paid or commence on the first payroll period of such subsequent calendar year following the Effective Release Date. The date on which your release of claims becomes effective is the
“Effective Release Date.” 
 (b) COBRA. In addition to Severance Pay, if you are
participating in the Company’s group health plan and/or dental plan at the time your employment ends and you exercise the right to continue participation in those plans under the federal law known as COBRA, or any successor law and if your
employment has ended for a reason other than resignation without Good Reason or termination for Cause, the Company will continue to pay the full premium for such coverage that is applicable for active and similarly-situated employees who receive the
same type of coverage (single, family, or other) until the earlier of (i) the end of the 12th month after your employment ends or (ii) the date your COBRA continuation coverage expires, unless the Company’s providing payments for
COBRA will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply. 
 (c)
Effect of Change of Control. If a Change of Control (as defined below) occurs and if, within one year following such Change of Control, the Company or any successor thereto terminates your employment other than for Cause, or you
terminate your employment for Good Reason, then, in addition to the Severance Pay, you will receive an amount equal to your then current target bonus (payable ratably in accordance with the Severance Pay). If the Change of Control is a 409A Change
of Control Event 

  
 3 

 
(as defined below), in lieu of installments, the Severance Pay and target bonus will be paid in a single lump sum in the Company’s next regular payroll period following the Effective Release
Date (subject to the same delay provided above where the 60 day period ends in the following year). A “409A Change of Control Event” is a “change in the ownership or effective control” of the Company or “change
in the ownership of a substantial portion of the assets” of the Company within the meaning of Treasury Regulation § 1.409A-3(i)(5). In addition, if a Change of Control occurs and if, within one year following such Change of Control,
(a) the Company or any successor thereto terminates your employment other than for Cause or your employment ends on death or disability, or (b) you terminate your employment for Good Reason, then all stock options held by you at such time
shall immediately vest in full, notwithstanding any contrary provision in any agreement evidencing any such stock option. 

(d) Definitions. 

i. For purposes of this Agreement, “Cause” shall include (i) your conviction or plea of guilty or
nolo contendre to a crime involving moral turpitude which adversely affects your ability to perform your obligations to the Company or the business activities, reputation, goodwill or image of the Company or to a felony, (ii) your
deliberate dishonesty or breach of fiduciary duty which could be reasonably expected to or does cause material loss, damage or injury to the Company, (iii) your material breach of the terms of this agreement or your failure or refusal to carry
out any material tasks assigned to you by the Company in accordance with the terms hereof, which breach or failure (only as to those susceptible to cure) continues for a period of more than ten days after your receipt of written notice thereof and
which could be reasonably expected to or does cause material loss, damage or injury to the Company, (iv) the commission by you of any act of fraud, embezzlement or deliberate disregard of a rule or policy of the Company known to you or
contained in a policy and procedure manual provided to you which could be reasonably expected to or does cause material loss, damage or injury to the Company, or (v) the material breach or threatened breach by you of any of the provisions of
the Confidentiality Agreement which could be reasonably expected to or does cause material loss, damage or injury to the Company. (“Company,” for purposes of this section, shall include the Company and any Company
subsidiary.) 
 ii. “Good Reason” shall mean, without your consent: (i) material diminution in
the nature or scope of your responsibilities, duties or authority, provided that neither of the following (x) or (y) shall constitute Good Reason: (x) the Company’s failure to continue your appointment or election as a director
or officer of any of its Affiliates nor (y) any diminution in the nature or scope of your responsibilities, duties or authority that is reasonably related to a diminution of the business of the Company or any of its Affiliates,

  
 4 

 
other than any such diminution resulting from the sale or transfer of any or all of the assets of the Company or any of its Affiliates; (ii) a material reduction in your base salary other
than one temporary reduction of not more than 120 days and not in excess of 20% of your base salary in connection with and in proportion to a general reduction of the base salaries of the Company’s executive officers; (iii) relocation of
your office more than 35 miles from Lexington, Massachusetts; or (iv) material breach by the Company of any material provision of this Agreement or any other service-providing agreement between the Company or any of its Affiliates and you. 

iii. “Change of Control” shall mean (i) the acquisition of beneficial ownership (as defined in
Rule 13d-3 under the Exchange Act) directly or indirectly by any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act), of securities of the Company representing a majority or more of the combined voting power of
the Company’s then outstanding securities, other than an acquisition of securities for investment purposes pursuant to a bona fide financing of the Company; (ii) a merger or consolidation of the Company with any other corporation in which
the holders of the voting securities of the Company prior to the merger or consolidation do not own more than 50% of the total voting securities of the surviving corporation; (iii) the sale or disposition by the Company of all or substantially
all of the Company’s assets other than a sale or disposition of assets to an entity whose equity interests are held, directly or indirectly, entirely by the same persons and in the same proportions as the equity interests of the Company; or
(iv) a change in the composition of the Board that results, during any one year period, in the Continuing Directors’ no longer constituting a majority of the Board (or, if applicable, the board of directors of a successor corporation to
the Company), where the term “Continuing Director” means at any date a member of the Board (x) who was a member of the Board on January 16, 2014 or (y) who was nominated or elected subsequent to such date by at
least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time
of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office after January 16, 2014 occurred as a result of an actual or threatened election
contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board. 

8. Withholdings; Section 409A. Anything to the contrary notwithstanding, (a) all payments required to be made by the
Company hereunder to you shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions as the Company 

  
 5 

 
may reasonably determine it should withhold pursuant to any applicable law or regulation, and (b) if and to the extent any portion of any payment, compensation or other benefit provided to
you in connection with your employment termination is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A and you are a specified employee as defined in Section 409A(a)(2)(B)(i), as
determined by the Company in accordance with its procedures, by which determination you hereby agree that you are bound, such portion of the payment, compensation or other benefit shall not be paid before the earlier of (i) the expiration of
the six month period measured from the date of your “separation from service” (as determined under Section 409A) or (ii) the tenth day following the date of your death following such separation from service (the “New
Payment Date” ). The aggregate of any payments that otherwise would have been paid to you during the period between the date of separation from service and the New Payment Date shall be paid to you in a lump sum in the first payroll
period beginning after such New Payment Date, and any remaining payments will be paid on their original schedule. For purposes of this Agreement, (i) each amount to be paid or benefit to be provided shall be construed as a separate identified
payment for purposes of Section 409A, (ii) neither you nor the Company shall have the right to accelerate or defer any payment or benefit hereunder unless permitted or required by Section 409A, and (iii) any payments that are due
within the “short term deferral period” as defined in Section 409A or paid in a manner consistent with Treas. Reg. § 1.409A-1(b)(9)(iii) shall not be treated as deferred compensation unless applicable law requires otherwise. The
terms of this employment letter are intended to be compliant with, or exempt from, Section 409A; provided, however, that the Company shall have no liability to you or to any other person in the event that the employment letter terms are
determined not to be so compliant or exempt. 
 9. Parachute Taxation. The Company will make any payments due to you without
regard to whether Section 280G of the Code would limit or preclude the deductibility of such payments (or any other payments or benefits) and without regard to whether such payments would subject you to the federal excise tax levied on certain
“excess parachute payments” under Section 4999 of the Code; provided, however, that if the Total After-Tax Payments (as defined below) would be increased by the reduction or elimination of any payment and/or other benefit (including
the vesting of any equity awards), then the amounts payable under this Agreement or otherwise will be reduced or eliminated as follows, as determined by the Company, in the following order: (i) nonacceleration of any stock options whose
exercise price is at or above the fair market value of the Company’s common stock as determined in the discretion of the Compensation Committee (taking into account, as appropriate, the proceeds that would be received in connection with the
event covered by Section 4999) (“Underwater Options”), (ii) nonacceleration of any stock options other than Underwater Options, (iii) any vesting or distribution of restricted stock or restricted stock units,
(iv) any other taxable benefits, (v) any nontaxable benefits, and (vi) the cash severance due under Section 7(a) above. Within each category described in clauses (i), (ii), and (iii), reductions or eliminations shall be made in
reverse order beginning with vesting or distributions that are to be paid the farthest in time from the date of the event covered by Section 4999. The Company’s independent, certified public accounting firm will determine whether and to
what extent payments or vesting under this Agreement are required to be reduced in accordance with the preceding sentence. If there is an underpayment or overpayment under this Agreement (as determined after the application of this paragraph), the
amount of such underpayment or overpayment will be immediately paid to you or refunded by you, as the case may be, with interest at the applicable federal rate provided for in 

  
 6 

 
Section 7872(f)(2) of the Code. For purposes of this Agreement, “Total After-Tax Payments” means the total of all “parachute payments” (as that term is
defined in Section 280G(b)(2) of the Code) made to you or for your benefit (whether made under the Agreement or otherwise), after reduction for all applicable federal taxes (including the tax described in Section 4999 of the Code). 

10. Miscellaneous. 

(a) Notices. All notices required or permitted under this Agreement must be in writing and will be deemed
effective upon personal delivery or three business days following deposit in a United States Post Office, by certified mail, postage prepaid, or one business day after it is sent for next-business day delivery via a reputable nationwide overnight
courier service addressed in the case of notice to the Company at its then principal headquarters (with copies to the Chairman of the Board and the Company’s General Counsel, which will not constitute notice), and in the case of notice to you
to the current address on file with the Company. Either Party may change the address to which notices are to be delivered by giving notice of such change to the other Party in the manner set forth in this Section 10(a) 

(b) No Mitigation. You are not required to seek other employment or otherwise mitigate the value of any severance
benefits contemplated by this Agreement, nor will any such benefits be reduced by any earnings or benefits that you may receive from any other source. Notwithstanding any other provision of this Agreement, any sum or sums paid under this Agreement
will be in lieu of any amounts to which you may otherwise be entitled under the terms of any severance plan, policy, program, agreement or other arrangement sponsored by the Company or an affiliate of the Company. 

(c) Waiver of Jury Trial. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, THE PARTIES
HEREBY WAIVE, AND COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR OTHER PROCEEDING ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE
RELEASE IT CONTEMPLATES, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE PARTIES AGREE THAT ANY PARTY MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY
AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE THEIR RIGHTS TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT OR TO ANY OF THE MATTERS CONTEMPLATED UNDER THIS AGREEMENT, RELATING TO YOUR
EMPLOYMENT, OR COVERED BY THE CONTEMPLATED RELEASE. 
 (d) Severability. Each provision of this Agreement is
intended to be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of
such prohibition or invalidity, 

  
 7 

 
without invalidating the remainder of such provision or the remaining provisions of this Agreement. Moreover, if an arbitrator or a court of competent jurisdiction determines any of the
provisions contained in this Agreement to be unenforceable because the provision is excessively broad in scope, whether as to duration, activity, geographic application, subject or otherwise, it will be construed, by limiting or reducing it to the
extent legally permitted, so as to be enforceable to the extent compatible with then applicable law to achieve the intent of the Parties. 

(e) Assignment. This Agreement will be binding upon and will inure to the benefit of (i) your heirs,
beneficiaries, executors and legal representatives upon your death and (ii) any successor of the Company. Any such successor of the Company will be treated as substituted for the Company under the terms of this Agreement for all purposes. The
Company may assign this Agreement without your consent, and such an assignment will not terminate your employment for purposes of triggering your entitlement to severance. You specifically agree that any assignment may include rights under the
Confidentiality Agreement without requiring your consent. As used herein, “successor” will mean any person, firm, corporation or other business entity that at any time, whether by purchase, merger or otherwise, directly or
indirectly acquires all or substantially all of the assets or business of the Company and its subsidiaries. None of your rights to receive any form of compensation payable under this Agreement will be assignable or transferable except through a
testamentary disposition or by the laws of descent and distribution upon your death or as provided in Section 10(k). Any attempted assignment, transfer, conveyance or other disposition of any interest in your rights to receive any form of
compensation hereunder, except as provided in the preceding sentence, will be null and void. 
 (f) No Oral
Modification, Waiver, Cancellation or Discharge. This Agreement may only be amended, canceled or discharged or any obligations thereunder waived through a writing signed by you and the Board or any duly authorized executive officer of the
Company. 
 (g) No Conflict of Interest. You confirm that you have fully disclosed to the Company and its
affiliates, to the best of your knowledge, any circumstances under which you, your immediate family and other persons who reside in your household have or may have a conflict of interest with the Company. You further agree to fully disclose to the
Company any such circumstances that might arise during your employment upon your becoming aware of such circumstances. 
 (h)
Other Agreements. You hereby represent that your performance of all the terms of this Agreement and the performance of your duties as an employee of the Company does not and will not breach any agreement to keep in confidence
proprietary information, knowledge or data acquired by you in confidence or in trust prior to your employment with the Company. You also represent that you are not a party to or subject to any restrictive covenants, legal restrictions, policies,
commitments or other agreements in favor of any entity or person that would in any way preclude, inhibit, impair or limit your ability to perform your obligations under this Agreement, including noncompetition agreements or nonsolicitation
agreements, and you further represent that your performance of the duties and obligations under this Agreement does not violate the terms of any agreement to which you are a party. You agree that you will not enter into any agreement or commitment
or agree to any policy that would prevent or unreasonably hinder your performance of duties and obligations under this Agreement. 

  
 8 

 (i) Disclosure of this Agreement. You acknowledge that the Company
may provide persons or entities who may employ or engage you with a copy of the Confidentiality Agreement (or portions thereof) to highlight your continuing obligations to the Company. You also acknowledge that the Company may be obligated to
disclose this Agreement or any portion thereof to satisfy applicable laws and regulations. You too are permitted to share a copy of the Confidentiality Agreement (or portions thereof) to the extent necessary to highlight your continuing obligations
to the Company. 
 (j) Survivorship. The respective rights and obligations of the Company and you hereunder
will survive any termination of your employment to the extent necessary to preserve the intent of such rights and obligations. 

(k) Beneficiaries. You will be entitled, to the extent applicable law permits, to select and change the
beneficiary or beneficiaries to receive any compensation or benefit payable hereunder upon your death by giving the Company written notice thereof in a manner consistent with the terms of any applicable plan documents. If you die, severance then due
or other amounts due hereunder will be paid to your designated beneficiary or beneficiaries or, if none are designated or none survive you, your estate. 

(l) Company Policies. References in this Agreement to Company policies and procedures are to those policies and
procedures in effect at the Effective Date, as the Company may amend them from time to time. 
 (m) Governing Law;
Dispute Resolution. This Agreement must be construed, interpreted, and governed in accordance with the laws of the Commonwealth of Massachusetts without reference to rules relating to conflict of law. The Parties agree that the Federal
Arbitration Act, 9 U.S.C. §1 et seq. and the American Arbitration Association’s National Rules for the Resolution of Employment Disputes (the “National Rules”) apply to the interpretation and enforcement of this
Agreement. In case of any controversy, dispute, or claim directly or indirectly arising out of or related to this Agreement, or the breach thereof, or relating to your employment (including claims relating to employment discrimination), except as
expressly excluded herein, each Party agrees to give the other Party notice of an intent to seek arbitration under this Agreement and 10 days to reach a resolution. Should resolution of any controversy or claim not be reached following provision of
notice and a reasonable opportunity to cure, then the Parties agree that any controversy or claim arising out of or relating to this Agreement, including the arbitrability of the dispute itself, shall be settled by one arbitrator in accordance with
the National Rules in effect at the time the arbitration demand is filed or such other rules as may be mutually agreed to by the Parties. The dispute will be arbitrated in Boston, Massachusetts, absent mutual agreement of the Parties to another
venue. Any claim or controversy not submitted to arbitration in accordance with this Section 10(m) (other than as provided under the Confidentiality Agreement) will be waived, and thereafter no arbitrator, arbitration panel, tribunal, or court
will have the power to rule or make any award on any such claim or controversy. In determining a claim or controversy under this Agreement and in making an award, the arbitrator must consider the terms and provisions of this Agreement, as well as
all applicable federal, 

  
 9 

 
state, or local laws. The award rendered in any arbitration proceeding held under this Section 10(m) will be final and binding and judgment upon the award may be entered in any court having
jurisdiction thereof. Claims for workers’ compensation or unemployment compensation benefits are not covered by this Section 10(m). Also not covered by this Section 10(m) are claims by the Company or by you for temporary restraining
orders, preliminary injunctions or permanent injunctions (“equitable relief”) in cases in which such equitable relief would be otherwise authorized by law or pursuant to the Confidentiality Agreement. The Company will be
responsible for paying any filing fee of the sponsoring organization and the fees and costs of the arbitrator; provided, however, that if you initiate the claim, you will contribute an amount equal to the filing fee you would have incurred to
initiate a claim in the court of general jurisdiction in the Commonwealth of Massachusetts. Each party will pay for its own costs and attorneys’ fees, if any, provided that the arbitrator or court, as applicable, may award reasonable costs and
expenses in favor of the prevailing party. The Company and you agree that the decision as to whether a party is the prevailing party in an arbitration, or a legal proceeding that is commenced in connection therewith, will be made in the sole
discretion of the arbitrator or, if applicable, the court. Any action, suit or other legal proceeding with respect to equitable relief that is excluded from arbitration above must be commenced only in a court of the Commonwealth of Massachusetts
(or, if appropriate, a federal court located within the Commonwealth of Massachusetts), and the Company and you each consent to the jurisdiction of such a court. With respect to any such court action, the Parties hereto (i) submit to the
personal jurisdiction of such courts; (ii) consent to service of process by the means specified under Section 10(a); and (iii) waive any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to
personal jurisdiction, inconvenient forum, or service of process. 
 (n) Interpretation. The parties agree that
this Agreement will be construed without regard to any presumption or rule requiring construction or interpretation against the drafting party. References in this Agreement to “include” or “including” should be read as though
they said “without limitation” or equivalent forms. References to “day” or “days” are to calendar days, unless the Agreement specifically refers to “business” days. 

(o) Entire Agreement. This Agreement and any documents referred to herein represent the entire agreement of the
Parties and will supersede any and all previous contracts, arrangements or understandings between the Company and you relating to matters covered by this Agreement, including the version of this Agreement entered into as January 16, 2014. 

Signatures on Following Page 

  
 10 

 
	
	Very truly yours,
	
	 /s/ Roger D. Tung

	Roger D. Tung
	President and Chief Executive Officer

  

					
	Agreed and Accepted:				
			
	Signature:				
			
	 /s/ D. Ryan Daws
				 6/16/2014

	D. Ryan Daws				Date:

  
 11EX-10.13

 Exhibit 10.13 
 LOAN AND SECURITY AGREEMENT 
 THIS LOAN AND SECURITY AGREEMENT is made and dated
as of December 22, 2011 and is entered into by and between CONCERT PHARMACEUTICALS, INC., a Delaware corporation, and each of its subsidiaries other than Concert Pharmaceuticals Securities Corporation, (hereinafter collectively referred
to as the “Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”). 
 RECITALS 
 A. Borrower has requested Lender to make available to Borrower a
loan in an aggregate principal amount of up to $20,000,000 (the “Term Loan”); and 
 B. Lender is willing to make the
Term Loan on the terms and conditions set forth in this Agreement. 
 AGREEMENT 

NOW, THEREFORE, Borrower and Lender agree as follows: 
 SECTION 1. DEFINITIONS AND RULES OF CONSTRUCTION  

1.1 Unless otherwise defined herein, the following capitalized terms shall have the following meanings: 

“Account Control Agreement(s)” means any agreement entered into by and among the Lender, Borrower and a third party Bank or
other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which grants Lender a perfected first priority security interest in the subject account or accounts.

 “ACH Authorization” means the ACH Debit Authorization Agreement in substantially the form of Exhibit H.

 “Advance(s)” means a Term Advance. 
 “Advance Date” means the funding date of any Advance. 
 “Advance
Request” means a request for an Advance submitted by Borrower to Lender in substantially the form of Exhibit A. 

“Agreement” means this Loan and Security Agreement, as amended from time to time. 

“Assignee” has the meaning given to it in Section 11.13. 

  
 1 

 “Borrower Products” means all products, technical data or technology currently
being developed, manufactured or sold by Borrower or which Borrower intends to sell, manufacture, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, technical
data or technology that have been sold, developed, licensed or distributed by Borrower since its incorporation. 

“Cash” means all cash and liquid funds. 
 “Change in Control” means any (i) reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions) of Borrower in which the holders of
Borrower’s outstanding shares immediately before consummation of such transaction or series of related transactions (together with any affiliates of such holders) do not, immediately after consummation of such transaction or series of related
transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly
owned by such parent), in each case without regard to whether Borrower is the surviving entity, or (ii) sale or issuance by Borrower of new shares of Preferred Stock of Borrower to investors, none of whom are current investors in Borrower (or
their affiliates), representing more than fifty percent (50%) of the voting power of the surviving entity (or the parent of such surviving entity if such surviving entity is wholly owned by such parent); provided, however, none of (a) an
Initial Public Offering or (b) a bona fide equity financing for the purpose of raising capital from institutional investors reasonably acceptable to Lender, shall not constitute a Change in Control. 

“Claims” has the meaning given to it in Section 11.10. 

“Closing Date” means the date of this Agreement. 
 “Collateral” means the property described in Section 3. 

“Commitment Fee” means $20,000, which fee Lender received prior to the Closing Date, and shall be deemed fully earned on such
date regardless of the early termination of this Agreement. 
 “Confidential Information” has the meaning given to it
in Section 11.12. 
 “Contingent Obligation” means, as applied to any Person, any direct or indirect liability,
contingent or otherwise, of that Person with respect to (i) any Indebtedness of another, including any such obligation guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is
otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any
interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or
commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount

  
 2 

 
equal to the stated or determined amount of the primary obligation described in clauses (i) and (ii) above in respect of which such Contingent Obligation is made or, if not stated or
determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or
other support arrangement. 
 “Copyright License” means any written agreement granting any right to use any Copyright
or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 
 “Copyrights” means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof, or of any other country. 

“Deposit Accounts” means any “deposit accounts,” as such term is defined in the UCC, and includes any checking
account, savings account, or certificate of deposit. 
 “ERISA” is the Employee Retirement Income Security Act of
1974, and its regulations, as amended and in effect from time to time. 
 “Event of Default” has the meaning given to
it in Section 9. 
 “Facility Charge” means 0.75% of the Maximum Term Loan Amount. 

“Financial Statements” has the meaning given to it in Section 7.1. 

“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time,
provided that the parties agree that GAAP as in effect on the date of this Agreement shall be applicable for the interpretation of “capital lease obligations” in the definition of “Indebtedness”, unless the parties otherwise
agree in writing. 
 “Grant Document” means an instrument or agreement providing that the Borrower or another Person
or both shall provide funding for or share the costs of programs identified in such instruments or agreements entered into in the OCB. 
 “Grant Requirements” means all obligations of Borrower to provide funding for or share the costs of, programs identified in Grant Documents or to perform other obligations thereunder.

 “GSK Agreement” means that certain Research and Development Collaboration and License Agreement by and between
Glaxo Group Limited and Concert Pharmaceuticals dated May 29, 2009, as amended. 
 “Indebtedness” means
(a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within ninety (90) days), including reimbursement and other
obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations. 

  
 3 

 “Initial Public Offering” means an initial firm commitment underwritten offering
of Borrower’s common stock pursuant to a registration statement under the Securities Act of 1933 filed with and declared effective by the Securities and Exchange Commission. 

“Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other
bankruptcy or insolvency law, including assignments of all or substantially all of a Person’s assets for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or
other similar relief. 
 “Intellectual Property” means all of Borrower’s Copyrights; Trademarks; Patents;
Licenses; trade secrets, proprietary information (including pre-clinical, clinical and other data) and inventions; mask works; Borrower’s applications therefor and reissues, extensions, or renewals thereof; and Borrower’s goodwill
associated with any of the foregoing, together with Borrower’s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith. 

“Interest Rate” means for any day a per annum rate of interest equal to the greater of either (i) 8.50% plus the United
States Prime Rate as reported in The Wall Street Journal minus 5.25%, and (ii) 8.50%; provided, however, the Interest Rate shall in no case exceed 11.0% per annum. 

“Investment” means any beneficial ownership (including stock, partnership or limited liability company interests) of or in any
Person, or any loan, advance or capital contribution to any Person or the acquisition of all, or substantially all, of the assets of another Person. 
 “Joinder Agreements” means for each Subsidiary (other than Concert Pharmaceuticals Securities Corp.), a completed and executed Joinder Agreement in substantially the form attached hereto as
Exhibit G. 
 “Lender” has the meaning given to it in the preamble to this Agreement. 

“License” means any Copyright License, Patent License, Trademark License or other license of rights or interests from a third
party. 
 “Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security
interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a
security interest. 
 “Loan” means the Advances made under this Agreement. 

  
 4 

 “Loan Documents” means this Agreement, the Notes, the ACH Authorization, the
Account Control Agreements, the Joinder Agreements, all UCC Financing Statements and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby (excluding the Warrant), as the same may from time
to time be amended, modified, supplemented or restated. 
 “Material Adverse Effect” means an occurrence, on or after
the date of the last set of audited financials, that has a material adverse effect upon: (i) the business, operations, properties, assets or condition (financial or otherwise) of the Borrower and its Subsidiaries, taken as a whole, other than
an effect in and of itself reasonably attributable to (a) adverse results or delays in any nonclinical or clinical trial, including without limitation failure to demonstrate the desired safety or efficacy of any biologic or drug; (b) the
denial, delay or limitation of approval of, or taking of any other regulatory action by, the United States Food and Drug Administration or any other governmental entity with respect to any biologic or drug; (c) a change in or discontinuation of
a strategic partnership or other collaboration or license arrangement; or (d) a going concern qualification in a financial statement or audit report resulting solely from Borrower and its Subsidiaries having less than twelve months of cash; or
(ii) the ability of Borrower to perform the Secured Obligations when due in accordance with the terms of the Loan Documents, or the ability of Lender to enforce any of its rights or remedies with respect to the Secured Obligations; or
(iii) the Collateral or Lender’s Liens on the Collateral or the priority of such Liens, in each case, in the aggregate; it being understood that in the case of each of items (ii) and (iii) the effects listed in clauses (i)(a)
through (d) of this definition shall be disregarded. 
 “Maturity Date” means July 1, 2015, provided
Maturity Date will mean October 1, 2015 if the interest-only period is extended pursuant to Section 2.1(d). 

“Maximum Term Loan Amount” means $20,000,000. 
 “Maximum Rate” shall have the meaning assigned to such term in Section 2.3. 
 “Note(s)” means a Term Note. 
 “OCB” means in the ordinary
course of business and shall include collaboration or licensing transactions that are customary in the Borrower’s industry such as, or comparable with or lesser in scope than, the Borrower’s existing collaboration with GlaxoSmithKline.

 “Patent License” means any written agreement granting any right with respect to any invention on which a Patent is
in existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest. 

“Patents” means all letters patent of, or rights corresponding thereto, in the United States or in any other country, all
registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States or any other country. 
 “Permitted Indebtedness” means: (i) Indebtedness of Borrower arising under this Agreement or any other Loan Document; (ii) Indebtedness existing on the Closing Date which is disclosed
in Schedule 1A; (iii) Indebtedness in the principal amount of up to $200,000 

  
 5 

 
outstanding at any time secured by a lien described in clause (vii) of the defined term “Permitted Liens,”; (iv) Indebtedness to trade creditors incurred in the ordinary
course of business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement
obligations in connection with letters of credit that are secured by cash or cash equivalents and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to exceed $906,000 at any time outstanding; (viii) other Indebtedness in
an amount not to exceed $250,000 at any time outstanding; (ix) Contingent Obligations of up to $200,000 described on clause (iii) of the definition of Contingent Obligations entered into to mitigate risk and not for speculative purposes;
(x) Grant Requirements; (xi) Indebtedness among Borrowers or of Borrower to any non-Borrower Subsidiary; and (xii) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not
increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be. 
 “Permitted Investment” means: (i) Investments existing on the Closing Date which are disclosed in Schedule 1B; (ii) (a) marketable direct obligations issued or unconditionally
guaranteed by the United States of America or any agency or any State thereof maturing within twenty four months from the date of acquisition thereof, (b) commercial paper maturing no more than 270 days from the date of creation thereof and at
the time of the Investment having a rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000
maturing no more than twenty four months from the date of investment therein, (d) money market accounts; and (e) corporate debt obligations maturing no more than 24 months from the date of acquisition thereof and at the time of investment
having a rating of at least A3 or A- from either Standard & Poors or Moody’s Investor Service; (iii) repurchases of stock from former employees, directors, or consultants of Borrower under agreements approved by the
Borrower’s board of directors in an aggregate amount not to exceed $250,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to the repurchases; (iv) Investments accepted
in connection with Permitted Transfers; (v) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with,
customers or suppliers arising in the ordinary course of Borrower’s business; (vi) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not affiliates, in the
ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; (vii) Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis
of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by Borrower’s Board of Directors; (viii) Investments
consisting of travel advances or moving expenses in the ordinary course of business; (ix) Investments in existing or newly-formed Subsidiaries organized in the United States, provided that such Subsidiaries enter into a Joinder Agreement and
execute such other documents as shall be reasonably requested by Lender and de minimis Investments in Concert Pharmaceuticals Securities Corporation in connection with its liquidation or dissolution; (x) Investments in subsidiaries organized
outside of the United States approved in advance in writing by Lender; (xi) licenses, joint ventures, collaboration agreements, strategic alliances and 

  
 6 

 
similar arrangements in the OCB providing for the exclusive or nonexclusive licensing of technology, Intellectual Property, or Borrower Products, the development of technology, Intellectual
Property or Borrower Products, the assignment of ownership or co-ownership rights in connection with the foregoing, or the providing of technical support, provided that any cash Investments by Borrower in another Person (other than a Subsidiary that
has entered into a Joinder pursuant to the terms hereof) as part of the foregoing do not exceed $100,000 in the aggregate in any fiscal year; (xii) Investments made pursuant to any investment policy adopted by a Borrower after the Closing Date
and approved by Lender; (xiii) Investments of up to $200,000 in the aggregate at any time outstanding in connection with Grant Requirements; (xiv) Investments by Borrower in another Borrower; and (xv) additional Investments that do
not exceed $250,000 in the aggregate per fiscal year. 
 “Permitted Liens” means any and all of the following:
(i) Liens in favor of Lender; (ii) Liens existing on the Closing Date which are disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in
good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor in accordance with GAAP; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other
like Persons arising in the ordinary course of Borrower’s business and imposed without action of such parties; provided, that the payment thereof is not yet required; (v) Liens arising from judgments, decrees or attachments in
circumstances which do not constitute an Event of Default hereunder; (vi) the following deposits, to the extent made in the ordinary course of business: deposits under worker’s compensation, unemployment insurance, social security and
other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than
for the repayment of borrowed money) or to secure statutory obligations (other than liens arising under ERISA or environmental liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; (vii) Liens on
Equipment or software, other intellectual property, or other capital assets, constituting purchase money liens and liens in connection with capital leases securing Indebtedness permitted in clause (iii) of “Permitted Indebtedness”;
(viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or subleases and licenses granted in the OCB and not interfering in any material respect with the business of the licensor;
(x) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance proceeds securing the payment of
financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); (xii) statutory, common law and contractual
rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; (xiii) easements, zoning restrictions, rights-of-way and similar encumbrances on real
property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; (xiv) Liens on cash or cash equivalents securing obligations permitted under
clause (vii) of the definition of Permitted Indebtedness; (xv) Liens in connection with operating leases in the Equipment that is the subject of such leases; (xvi) Permitted Transfers; and (xvii) Liens incurred in connection with
the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in 

  
 7 

 
clauses (i) through (xvi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of
the indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase. 

“Permitted Transfers” means (i) sales of Inventory in the normal course of business, (ii) exclusive or non-exclusive
licenses, joint ventures, collaboration agreements, strategic alliances and similar arrangements in the OCB providing for the exclusive or nonexclusive licensing of technology, Intellectual Property or Borrower Products, the development of
technology, Intellectual Property or Borrower Products, the assignment of ownership or co-ownership rights in connection with the foregoing, or the providing of technical support, (iii) dispositions of worn-out, obsolete or surplus Equipment at
fair market value in the ordinary course of business, (iv) Permitted Investments, (v) Permitted Liens, (vi) dispositions of Copyright rights in connection with publications in scientific journals, and (vii) other Transfers of
assets having a fair market value of not more than $250,000 in the aggregate in any fiscal year. 
 “Person” means
any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government. 

“Preferred Stock” means at any given time any equity security issued by Borrower that has any rights, preferences or
privileges senior to Borrower’s common stock. 
 “Prepayment Charge” shall have the meaning assigned to such
term in Section 2.5. 
 “Receivables” means all of Borrower’s Accounts, Instruments, Documents, Chattel
Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit Rights. 

“Secured Obligations” means Borrower’s obligations under this Agreement and any Loan Document, including any obligation
to pay any amount now owing or later arising. 
 “Subordinated Indebtedness” means Indebtedness subordinated to the
Secured Obligations in amounts and on terms and conditions satisfactory to Lender in its sole discretion. 

“Subsidiary” means an entity, whether corporate, partnership, limited liability company, joint venture or otherwise, in which
Borrower owns or controls more than 50% of the outstanding voting securities, including each entity listed on Schedule 1 hereto. 
 “Term Advance” means any Term Loan funds advanced under this Agreement. 

“Term Note” means a Promissory Note in substantially the form of Exhibit B-1. 

  
 8 

 “Trademark License” means any written agreement granting any right to use any
Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 
 “Trademarks” means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States
Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof. 
 “UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the Commonwealth of Massachusetts; provided, that in the event that, by reason of mandatory provisions of
law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the
Commonwealth of Massachusetts, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection,
priority or remedies and for purposes of definitions related to such provisions. 
 “Warrant” means the warrant
entered into in connection with the Loan. 
 Unless otherwise specified, all references in this Agreement or any Annex or
Schedule hereto to a “Section,” “subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless
otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in
accordance with GAAP, consistently applied. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC.

 SECTION 2. THE LOAN 
 2.1 Term Loan. 
 (a) Advances. Subject to the terms and conditions
of this Agreement, Lender will make, and Borrower agrees to draw, a Term Advance of $7,500,000 (the “First Tranche”) on the Closing Date. Beginning on the Closing Date, and continuing through March 31, 2012, Borrower may request one
additional Term Advance in an aggregate amount up to $12,500,000 (the “Second Tranche”). The aggregate outstanding Term Advances may be up to the Maximum Term Loan Amount. 

(b) Advance Request. To obtain a Term Advance, Borrower shall complete, sign and deliver an Advance Request (which, as to
the Second Tranche, shall be at least five business days before the Advance Date) and Term Note to Lender. Lender shall fund the Term Advance in the manner requested by the Advance Request provided that each of the conditions precedent in
Section 4 of this Agreement applicable to such Term Advance is satisfied as of the requested Advance Date. 

  
 9 

 (c) Interest. The principal balance of each Term Advance shall bear interest
thereon from such Advance Date at the Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Interest Rate will float and change on the day the Prime Rate changes from time
to time. 
 (d) Payment. Borrower will pay interest on each Term Advance in arrears on the first business day of
each month, beginning the month after the Advance Date and ending on January 3, 2013 (the “Interest Only Period”). Borrower shall repay the aggregate Term Loan principal balance that is outstanding on the first anniversary of the
Closing Date in 30 equal monthly installments of principal and interest beginning February 1, 2013 and continuing on the first business day of each month thereafter. Notwithstanding the foregoing, Borrower may elect to postpone the date on
which the first such installment is due until May 1, 2013, (and the last payment date of the Interest Only Period shall be April 1, 2013), provided Borrower has begun the Proof of Concept study for CTP-499, meaning that the first patient
has been enrolled in a clinical study in which subjects with diabetes and reduced kidney function are randomly assigned to receive either placebo or CTP-499 treatment. The entire Term Loan principal balance and all accrued but unpaid interest
hereunder, shall be due and payable on Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the
Borrower’s account as authorized on the ACH Authorization on each payment date of all periodic obligations payable to Lender under each Term Note or Term Advance. 

2.2 Maximum Interest. Notwithstanding any provision in this Agreement, the Notes, or any other Loan Document, it is the
parties’ intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the Commonwealth of
Massachusetts shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”). If a court of competent jurisdiction shall finally determine that Borrower has actually paid to Lender an
amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows: first, to
the payment of principal outstanding on the Notes; second, after all principal is repaid, to the payment of Lender’s accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured
Obligations are repaid, the excess (if any) shall be refunded to Borrower. 
 2.3 Default Interest. In the event
any payment is not paid on the scheduled payment date, an amount equal to five percent (5%) of the past due amount shall be payable on demand. Upon the occurrence and during the continuation of an Event of Default hereunder, all Secured
Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set 

  
 10 

 
forth in Section 2.1(c) plus five percent (5%) per annum. In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear
interest on interest, compounded at the rate set forth in Section 2.1(c). 
 2.4 Prepayment. At its option
upon at least 7 business days prior notice to Lender, Borrower may prepay all, but not less than all, of the outstanding Advances by paying the entire principal balance, all accrued and unpaid interest, together with a prepayment charge equal to the
following percentage of the Advance amount being prepaid: if such Advance amounts are prepaid in any of the first twelve (12) months following the Closing Date, 3.0%; after twelve (12) months but prior to twenty four (24) months,
2.0%; and thereafter, 1.0% (each, a “Prepayment Charge”). Borrower agrees that the Prepayment Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining actual damages
resulting from an early repayment of the Advances. Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and the Prepayment Charge upon demand of the Lender made no later than 30 days
following a Change in Control. 
 SECTION 3. SECURITY INTEREST 

3.1 As security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the
Secured Obligations, Borrower grants to Lender a security interest in all of Borrower’s personal property now owned or hereafter acquired, including the following (collectively, the “Collateral”): (a) Receivables;
(b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual Property); (e) Inventory; (f) Investment Property (but excluding thirty-five percent (35%) of the capital stock of any foreign Subsidiary
that constitutes a Permitted Investment); (g) Deposit Accounts; (h) Cash; (i) Goods; and other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, or acquired by, Borrower and wherever
located; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing. Notwithstanding any of the foregoing, the
Collateral shall not under any circumstance include, and no security interest is granted in (i) Borrower’s Intellectual Property, provided, however, that the Collateral shall include all Accounts and General Intangibles that consist
of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Borrower’s Intellectual Property (the “Rights to Payment”); (ii) any capital stock of any foreign subsidiary that
constitutes a Permitted Investment in excess of 65% of such capital stock, provided that Lender’s taking a security interest in more than 65% of such stock would be reasonably expected to cause Borrower to incur adverse tax consequences;
(iii) any assets of Borrower that both (x) consist of compounds and raw materials used to manufacture biopharmaceuticals or which are used for preclinical testing or clinical trials, and (y) are located outside of the United States,
if and for so long as the grant of such security interest is prohibited by or requires a consent under any applicable requirement of law of a jurisdiction other than the United States or any state or other subdivision thereof, provided that the
Borrower shall not be required to undertake any steps under the laws of any applicable foreign jurisdiction with respect to the creation, perfection or priority of the Secured Party’s security interests in such assets; (iv) equipment

  
 11 

 
financed by capital leases or purchase money financing and all Borrower’s books and records relating to the foregoing, and any and all claims, rights and interest in such assets and all
substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing; and (v) any cash or cash equivalents described in clause
(vii) of the definition of Permitted Indebtedness. Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security
interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Lender’s security interest in the
Rights to Payment, except to the extent that such inclusion as Collateral could be inconsistent with or conflict with the GSK Agreement or any agreement entered into in connection with a Permitted Transfer or interfere with the parties’ rights
and remedies thereunder. 
 SECTION 4. CONDITIONS PRECEDENT TO LOAN 

The obligations of Lender to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions: 

4.1 Initial Advance. On or prior to the Closing Date, Borrower shall have delivered to Lender the following: 

(a) executed originals of the Loan Documents, Account Control Agreements, a legal opinion of Borrower’s counsel, and
all other documents and instruments reasonably required by Lender to effectuate the transactions contemplated hereby or to create and perfect the Liens of Lender with respect to all Collateral, in all cases in form and substance reasonably
acceptable to Lender; 
 (b) certified copy of resolutions of Borrower’s board of directors evidencing
approval of (i) the Loan and other transactions evidenced by the Loan Documents; and (ii) the Warrant and transactions evidenced thereby; 
 (c) certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower; 

(d) a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other
jurisdictions in which it does business and where the failure to be qualified would have a Material Adverse Effect; 
 (e) payment of the Facility Charge and reimbursement of Lender’s current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; and 

(f) such other documents as Lender may reasonably request. 

  
 12 

 4.2 All Advances. On each Advance Date: 

(a) Lender shall have received an Advance Request and a Note for the relevant Advance as required by Section 2.1(b),
as applicable, each duly executed by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer. 
 (b) The representations and warranties set forth in this Agreement and in Section 5 of this Agreement shall be true and correct in all material respects on and as of the Advance Date with the same
effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date. 
 (c) Borrower shall be in compliance in all material respects with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of
and immediately after such Advance no Event of Default shall have occurred and be continuing. 
 (d) Each Advance
Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance
Request. 
 4.3 No Default. As of the Closing Date and each Advance Date, as applicable, (i) no fact or
condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no Material Adverse Effect has occurred and is continuing. 

SECTION 5. REPRESENTATIONS AND WARRANTIES OF BORROWER 

Borrower represents and warrants that: 
 5.1 Corporate Status. Borrower is a corporation duly organized, legally existing and in good standing under the laws of the State of Delaware, and is duly qualified as a foreign corporation in all
jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect. Borrower’s present name, former
names (if any), owned and leased locations, place of formation, tax identification number, organizational identification number and other information are correctly set forth in Exhibit C, as may be updated by Borrower in a written notice (including
any Compliance Certificate) provided to Lender after the Closing Date. 
 5.2 Collateral. Borrower owns its
property, free of all Liens, except for Permitted Liens. Borrower has the corporate power and authority to grant to Lender a Lien in the Collateral as security for the Secured Obligations. 

5.3 Consents. Borrower’s execution, delivery and performance of the Notes, this Agreement and all other Loan
Documents, and Borrower’s execution of the Warrant, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted

  
 13 

 
Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate of Incorporation, bylaws, or any material law,
regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not violate any material contract or agreement or require the consent or approval of any other Person that has
not been obtained. The individual or individuals executing the Loan Documents and the Warrant on behalf of the Borrower are duly authorized to do so. 
 5.4 Material Adverse Effect. No Material Adverse Effect has occurred and is continuing. 
 5.5 Actions Before Governmental Authorities. Except as described on Schedule 5.5, there are no actions, suits or proceedings at law or in equity by or before any governmental authority now pending or, to
the knowledge of Borrower, threatened in writing against or affecting Borrower or its property as to which there is a reasonable likelihood of an adverse determination and which, if adversely determined, would reasonably be expected to, individually
or in the aggregate, result in a Material Adverse Effect. 
 5.6 Laws; Agreements. Borrower is not in violation
of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect. Borrower is not in
default in any manner under any provision of any agreement or instrument evidencing Indebtedness, or any other material agreement to which it is a party or by which it is bound, and which default would reasonably be expected to have a Material
Adverse Effect. 
 5.7 Information Correct and Current. No report, Advance Request, financial statement, exhibit
or schedule furnished, by or on behalf of Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto, when taken together with all such other reports, statements or other documents or writings, contains
any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading at the time such statement was made or deemed made.
Additionally, any and all financial or business projections provided by Borrower to Lender shall be at the time delivered (i) provided in good faith and based on the most current data and information available to Borrower, and (ii) the
most current of such projections provided to Borrower’s Board of Directors. 
 5.8 Tax Matters. Except as
described on Schedule 5.8, (a) Borrower has filed all material federal, state and local tax returns that it is required to file (or extensions thereof), (b) Borrower has duly paid or fully reserved (if required under GAAP) for all material
taxes or installments thereof (including any interest or penalties) as and when due, which have or may become due pursuant to such returns, and (c) Borrower has paid or fully reserved for any material tax assessment received by Borrower for the
three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by appropriate proceedings). 

  
 14 

 5.9 Intellectual Property Claims. Except for Permitted Liens, Borrower is
the sole owner of, or otherwise has the right to use, the Intellectual Property material to its business. Except as described on Schedule 5.9,(i) to Borrower’s knowledge, each of the material issued Copyrights, Trademarks and Patents is valid
and enforceable, (ii) no material Intellectual Property of Borrower has been judged by a decision of a court of competent jurisdiction, invalid or unenforceable, in whole or in part, and (iii) no claim has been made to Borrower in writing
that any material Intellectual Property of Borrower violates the rights of any third party except to the extent such claim would not reasonably be expected to cause a Material Adverse Effect. Exhibit D is a true, correct and complete list of each of
Borrower’s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from third parties (shrink-wrap software licenses and click on license agreements, open source code
and other licenses available to the public without customization shall not be considered a material License or agreement), together with application or registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the
Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to Borrower’s knowledge, no third party to any such contract,
license or agreement is in material breach thereof or has failed to perform any material obligations thereunder in each case which would reasonably be expected to have a Material Adverse Effect. 

5.10 Intellectual Property. Except as described on Schedule 5.10, Borrower has, or in the case of any proposed business,
will have, all material rights with respect to Intellectual Property necessary in the operation or conduct of Borrower’s business as currently conducted and proposed to be conducted by Borrower. Without limiting the generality of the foregoing,
other than in connection with Permitted Transfers, and in the case of material in-bound Licenses, except for restrictions that are unenforceable under Division 9 of the UCC and except as provided in the GSK Agreement, Borrower has the right, to the
extent required to operate Borrower’s business, to freely transfer, license or assign the Intellectual Property licensed pursuant to such material License without condition, restriction or payment of any kind (other than payments in the
ordinary course of business) to any third party, Borrower owns or has the right to use, pursuant to valid licenses, all material software development tools, library functions, compilers and other third-party software and other items that are
necessary for the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products that are currently being clinically developed, manufactured or sold by Borrower. For the avoidance of doubt,
shrink-wrap licenses, click on license agreements, open source code and other licenses available to the public without customization shall not be considered a material License. 

5.11 Borrower Products. Except as described on Schedule 5.11, no material Intellectual Property owned by Borrower or
Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened (in writing) litigation, inter-party proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding
foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any material respect Borrower’s use, 

  
 15 

 
transfer or licensing thereof or that may affect the validity, use or enforceability thereof. To Borrower’s knowledge, there is no decree, order, judgment, agreement, stipulation, arbitral
award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future material Intellectual Property related to the operation or conduct of the business of
Borrower or Borrower Products. Borrower has not received any written notice or claim challenging Borrower’s ownership in any material Intellectual Property (or written notice of any claim challenging the ownership in any material licensed
Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto. To Borrower’s knowledge, neither Borrower’s use of its material Intellectual Property nor
the production and sale of Borrower Products infringes in any material respect the Intellectual Property or other rights of others. 
 5.12 Financial Accounts. Exhibit E, as may be updated by the Borrower in a written notice provided to Lender after the Closing Date, is a true, correct and complete list of (a) all banks and other
financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies in all
material respects the name, address and telephone number of each bank or other institution, the name in which the account is held, and the complete account number therefor. 

5.13 Employee Loans. Except as permitted as a Permitted Investment, Borrower has no outstanding loans to any employee,
officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party. 

5.14 Capitalization and Subsidiaries. Borrower’s capitalization as of the Closing Date is set forth on Schedule 5.14
annexed hereto. Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date,
is a true, correct and complete list of each Subsidiary. 
 SECTION 6. INSURANCE; INDEMNIFICATION 

6.1 Coverage. Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence
form, against risks customarily insured against in Borrower’s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms
of the indemnification agreement found in Section 6.3. Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance (including umbrella coverage) for each occurrence. Borrower has and agrees to maintain a minimum of
$2,000,000 of directors and officers’ insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral,
insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard exceptions and deductibles. Borrower shall also
carry and maintain a fidelity insurance policy in an amount not less than $100,000. 

  
 16 

 6.2 Certificates. Borrower shall deliver to Lender certificates of insurance
that evidence Borrower’s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance certificate shall state Lender is an additional insured for commercial
general liability, an additional insured and a loss payee for all risk property damage insurance, subject to the insurer’s approval, a loss payee for fidelity insurance, and a loss payee for property insurance and additional insured for
liability insurance for any future insurance that Borrower may acquire from such insurer. Attached to the certificates of insurance will be additional insured endorsements for liability and lender’s loss payable endorsements for all risk
property damage insurance and fidelity. All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Lender of cancellation (except for 10 days for non payment). Any failure of Lender to scrutinize such
insurance certificates for compliance is not a waiver of any of Lender’s rights, all of which are reserved. 

6.3 Indemnity. Borrower agrees to indemnify and hold Lender and its officers, directors, employees, agents, in-house
attorneys, representatives and shareholders harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict
liability in tort), including reasonable attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal), that may be instituted or asserted against or incurred by Lender or any such
Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and
thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases claims resulting from Lender’s or any indemnitee’s gross negligence or
willful misconduct. Borrower agrees to pay, and to save Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar taxes (excluding taxes imposed on or measured by
the net income of Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement; provided, however, that (i) with respect to such liabilities imposed originally and independently on Lender,
Lender shall notify a Borrower of any such liabilities within 180 days of the initial date Lender had actual knowledge of Lender’s direct exposure to such liabilities, and (ii) with respect to all other such liabilities not described in
subsection (i), Lender shall notify Borrower of any such liabilities within 180 days of the initial date Lender has actual knowledge of its direct exposure to such liabilities. 

SECTION 7. COVENANTS OF BORROWER 
 Borrower agrees as follows: 
 7.1 Financial Reports. Borrower shall
furnish to Lender the financial statements and reports listed hereinafter (the “Financial Statements”): 
 (a) as soon as practicable (and in any event within 30 days) after the end of each month, unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated
basis, if applicable), including balance sheet and related statements of income and cash flows, all certified on behalf of Borrower by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer to the effect that
they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject
to adjustment with respect to revenue recognition for upfront and milestone payments. 

  
 17 

 (b) as soon as practicable (and in any event within 45 days) after the end
of each of the first three calendar quarters of each year (I) unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated basis, if applicable), including balance sheet and related
statements of income and cash flows, certified on behalf of Borrower by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except
(i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect to revenue recognition for
upfront and milestone payments; and (II) before an Initial Public Offering, the most recent capitalization table for Borrower, including the weighted average exercise price of employee stock options. 

(c) (I) as soon as practicable and in any event within sixty (60) days after the end of each fiscal year,
preliminary financial statements as of the end of such fiscal year (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows, certified on behalf of Borrower by Borrower’s Chief
Executive Officer, Chief Operating Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments,
(iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect to revenue recognition for upfront and milestone payments; (II) before an Initial Public Offering, as soon as practicable and in
any event within sixty (60) days after the end of each fiscal year, the most recent capitalization table for Borrower, including the weighted average exercise price of employee stock options; and (III) as soon as practicable and in any event
within one hundred eighty (180) days) after the end of each fiscal year, audited financial statements as of the end of such year (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and
cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Lender, accompanied by an
audit report from such accountants which is unqualified as to scope of audit; 
 (d) as soon as practicable (and
in any event within 30 days) after the end of each month, a Compliance Certificate in the form of Exhibit F; 

  
 18 

 (e) promptly after the sending or filing thereof, as the case may be, copies
of any proxy statements, financial statements or reports that Borrower has made available generally to holders of its Preferred Stock and copies of any regular, periodic and special reports or registration statements that Borrower files with the
Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange; 
 (f) Before an Initial Public Offering, at the same time and in the same manner as it gives to its Board of Directors, copies of all notices, minutes, consents and other materials that Borrower provides to
its Board of Directors in connection with meetings of the Board of Directors, and minutes of such meetings, provided Borrower may exclude from such delivery any materials, the disclosure of which would reasonably be expected to constitute or effect
a waiver of the attorney-client privilege; 
 (g) financial and business projections promptly following their
approval by Borrower’s Board of Directors, as well as budgets, operating plans; and 
 (h) other financial
information reasonably requested by Lender. 
 Borrower shall not make any change in its fiscal years or fiscal quarters or,
without notice to Lender, any change in its accounting policies or reporting practices. The fiscal year of Borrower shall end on December 31. 
 The executed Compliance Certificate may be sent via facsimile to Lender at (650) 473-9194 or via e-mail to jbourque @herculestech.com. All Financial Statements required to be delivered pursuant to
clauses (a), (b) and (c) shall be sent via e-mail to financialstatements@herculestech.com with a copy to jbourque@herculestech.com provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible,
they shall be sent via facsimile to Lender at: (866) 468-8916, attention Chief Credit Officer. 
 7.2
Management Rights. Borrower shall permit any representative that Lender authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at
reasonable times and upon reasonable notice during normal business hours (but in any event no more than once in any12-month period unless an Event of Default has occurred and is continuing). In addition, any such representative shall have the right
to meet with management and officers of Borrower to discuss such books of account and records. In addition, Lender shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning
significant business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower’s business operations. The parties intend that the rights granted Lender shall constitute “management rights” within the
meaning of 29 C.F.R Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Lender with respect to any business issues shall not be deemed to give Lender, nor be deemed an exercise by Lender of, control over
Borrower’s management or policies. 

  
 19 

 7.3 Further Assurances. Borrower shall from time to time execute, deliver
and file, alone or with Lender, any financing statements, security agreements, collateral assignments, notices, control agreements, or other necessary documents to perfect or give to Lender a first priority Lien on the Collateral (subject to
Permitted Liens). Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Lender, and take all further action that may be necessary or desirable, or that Lender may reasonably request, to perfect and
protect the Liens granted hereby and thereby. In addition, and for such purposes only, Borrower hereby authorizes Lender to execute and deliver on behalf of Borrower and to file such financing statements, collateral assignments, notices, control
agreements, security agreements and other documents without the signature of Borrower either in Lender’s name or in the name of Lender as agent and attorney-in-fact for Borrower. Borrower shall in its reasonable business judgment protect and
defend Borrower’s title to the Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower or Lender other than Permitted Liens. 

7.4 Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any
Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness at any time before the Maturity Date, except for the
conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion. 
 7.5 Encumbrances. Borrower shall at all times keep its property free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice when the Borrower knows
of any legal process affecting such property, or any Liens thereon. Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its property from and against all Persons claiming any interest adverse to such
Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s property free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice when the Borrower knows of
any legal process affecting such Subsidiary’s property. Borrower shall not enter into any agreement with any Person other than Lender (other than in connection with Permitted Liens and Permitted Transfers) that has the effect of restricting
Borrower from granting a Lien on its Intellectual Property to Lender. 
 7.6 Investments. Borrower shall not
directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries so to do, other than Permitted Investments. 
 7.7 Distributions. Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than (i) pursuant to employee, director
or consultant repurchase plans or other similar agreements, in an aggregate amount not to exceed $250,000, or (ii) pursuant to Section 4 of the Third Amended and Restated Right of First Refusal and Co-Sale Agreement dated as of
June 1, 2009 provided that any such repurchase is approved by the Borrower’s Board of Directors, in an aggregate amount not to exceed $500,000, (b) declare or pay any cash dividend or

  
 20 

 
make a cash distribution on any class of stock or other equity interest, except that a Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to any employees,
officers or directors or guarantee the payment of any such loans granted by a third party other than Permitted Investments. 
 7.8 Transfers. Except for Permitted Transfers, Permitted Investments and Permitted Liens, Borrower shall not voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey
any equitable, beneficial or legal interest in any material portion of their assets. 
 7.9 Mergers or
Acquisitions. (a) Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or
into Borrower), (b) Borrower shall not acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person other than Permitted Investments. Borrower may dissolve any Subsidiary as
long as the assets of that Subsidiary are promptly distributed to such Subsidiary’s shareholder. 
 7.10
Taxes. Borrower and its Subsidiaries shall pay when due all material taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Lender or the
Collateral or upon Borrower’s ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom. Borrower shall file on or before the due date therefor all personal property tax
returns (or extensions) in respect of the Collateral. Notwithstanding the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves therefor in accordance with GAAP.

 7.11 Corporate Changes. 

(a) Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without
twenty (20) days’ prior written notice to Lender. 
 (b) The Borrower shall not suffer a Change in
Control. 
 (c) Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal
place of business unless: (i) it has provided prior written notice to Lender; and (ii) such relocation shall be within the continental United States. 
 (d) Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (v) Borrower Products, including compounds and raw materials used to manufacture biopharmaceuticals or which
are used for preclinical testing or clinical trials, in the ordinary course of business, (w) Permitted Transfers, (x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment having an aggregate value of up
to $150,000 in any fiscal year, and (z) relocations of Collateral from a location described on Exhibit C to another location described on Exhibit C) unless (i) it has 

  
 21 

 
provided prompt written notice to Lender, (ii) such relocation is within the continental United States and, (iii) if such relocation is to a third party bailee, and the Collateral has a
value in excess of $250,000, it has delivered a bailee agreement in form and substance reasonably acceptable to Lender. 
 7.12 Deposit Accounts. Neither Borrower nor any Subsidiary shall maintain any Deposit Accounts constituting Collateral (other than payroll accounts or accounts holding trust fund taxes), or accounts
holding Investment Property constituting Collateral, except with respect to which Lender has an Account Control Agreement, if applicable. 
 7.13 Subsidiaries. Borrower shall notify Lender of each Subsidiary formed subsequent to the Closing Date and, within 15 days of formation, shall cause any such Subsidiary organized under the laws of any
State within the United States to execute and deliver to Lender a Joinder Agreement. 
 SECTION 8. RESERVED

 8.1 Reserved. 
 SECTION 9. EVENTS OF DEFAULT 
 The occurrence of any one or more of
the following events shall be an Event of Default: 
 9.1 Payments. Borrower fails to pay any amount due under
this Agreement, the Notes or any of the other Loan Documents on the due date, and in each case such default continues for more than 3 business days after the due date thereof; or 

9.2 Covenants. Borrower breaches or defaults in the performance of any covenant under any of the Loan Documents, and
(a) with respect to a default under any such covenant under this Agreement (other than under Sections 6.1, 7.5, 7.6, 7.7, 7.8, 7.9 or 7.11) such default continues for more than ten (10) business days after the earlier of the date on which
(i) Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default, or (b) with respect to a default under any of Sections 6.1, 7.5, 7.6, 7.7, 7.8 or 7.9, (b) the occurrence of such
default, or (c) with respect to a default under any of Sections 7.9(a) and 7.11(b), the Lender has given notice of such default to Borrower no later than 30 days after a Change of Control; or 

9.3 Material Adverse Effect. An event has occurred that would reasonably be expected to have a Material Adverse Effect; or

 9.4 Other Loan Documents. The occurrence of any default under any Loan Document, the Warrant or any other
agreement between Borrower and Lender and such default continues for more than ten business (10) days after the earlier of (a) Lender has given notice of such default to Borrower, or (b) Borrower has actual knowledge of such default;
or 

  
 22 

 9.5 Representations. Any representation or warranty made by Borrower in any
Loan Document or in the Warrant shall have been false or misleading in any material respect; or 
 9.6
Insolvency. Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay the Secured Obligations under the Loan Documents, or shall become
insolvent; or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar
relief under any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part
(i.e., 33-1/3% or more) of the assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally been conducted for 3 consecutive business days, or terminate substantially all of its employees; or
(vii) Borrower or its directors or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) sixty (60) days shall have expired after the
commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being
dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be
timely appealed; or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter
a decree or order granting the relief sought in any such proceedings; or (v) forty five (45) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower
or of all or any substantial part of the properties of Borrower without such appointment being vacated; or 
 9.7
Attachments; Judgments. Any portion of Borrower’s assets having a value in excess of $350,000 is attached or seized, or a levy is filed against any such assets, or a judgment or judgments (not covered by insurance as to which an insurer not
affiliated with Borrower has acknowledged coverage) is/are entered for the payment of money, individually or in the aggregate, of at least $350,000, and remains unstayed, unbonded and unsatisfied for more than 30 days, or Borrower is enjoined or in
any way prevented by court order from conducting any material part of its business; or 
 9.8 Other Obligations.
The occurrence of any default under any agreement or obligation of Borrower involving any Indebtedness in excess of $175,000. 

SECTION 10. REMEDIES 
 10.1 General. Upon and during the continuance of any one or more Events of Default, (i) Lender may, at its option, accelerate and demand payment of all or any part of the Secured Obligations together
with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of 

  
 23 

 
the type described in Section 9.6, the Notes and all of the Secured Obligations shall automatically be accelerated and made due and payable, in each case without any further notice or act),
and (ii) Lender may notify any of Borrower’s account debtors to make payment directly to Lender, compromise the amount of any such account on Borrower’s behalf and endorse Lender’s name without recourse on any such payment for
deposit directly to Lender’s account. Lender may exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold,
sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral. All Lender’s rights and remedies shall be cumulative and not
exclusive. 
 10.2 Collection; Foreclosure. Upon the occurrence and during the continuance of any Event of
Default, Lender may, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or
processing, in such order as Lender may elect. Any such sale may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’
prior written notice to Borrower. Lender may require Borrower to assemble the Collateral and make it available to Lender at a place designated by Lender that is reasonably convenient to Lender and Borrower. The proceeds of any sale, disposition or
other realization upon all or any part of the Collateral shall be applied by Lender in the following order of priorities: 

First, to Lender in an amount sufficient to pay in full Lender’s costs and professionals’ and advisors’ fees and expenses
as described in Section 11.11; 
 Second, to Lender in an amount equal to the then unpaid amount of the Secured Obligations
(including principal, interest, and the Default Rate interest), in such order and priority as Lender may choose in its sole discretion; and 
 Finally, after the full and final payment in Cash of all of the Secured Obligations, to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of
competent jurisdiction may direct. 
 Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the
Collateral if it complies with the obligations of a secured party under the UCC. 
 10.3 The Lender agrees not to
issue a notice of exclusive control or any other instruction under any Account Control Agreement unless an Event of Default has occurred and is continuing. 
 10.4 No Waiver. Lender shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Lender to
marshal any Collateral. 
 10.5 Cumulative Remedies. The rights, powers and remedies of Lender hereunder shall be
in addition to all rights, powers and remedies given by statute or rule of 

  
 24 

 
law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other
rights, powers and remedies of Lender. 
 SECTION 11. MISCELLANEOUS 

11.1 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 11.2 Notice.
Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) (a “Notification”) that is required, contemplated,
or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by
facsimile or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed
to the party to be notified as follows: 
 (a) If to Lender: 

HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 

Legal Department 
 Attention: Chief Legal Officer and Janice Bourque 
 400 Hamilton
Avenue, Suite 310 
 Palo Alto, CA 94301 

Facsimile: 650-473-9194 
 Telephone: 650-289-3060 
 With a copy to: 

HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 

31 St. James Ave., Suite 790 
 Boston, MA 02116 
 Attention: Janice Bourque 

Facsimile:
617-                     
 Telephone: 617-314-9992 
 (b) If to Borrower: 

CONCERT PHARMACEUTICALS, INC. 

99 Hayden Ave., Suite 500 
 Lexington, MA 02421 
 Attention: Nancy Stuart 

Chief Operating Officer 
 Facsimile: 
 Telephone: 

  
 25 

 With a copy (that shall not constitute notice) to: 

Wilmer Cutler Pickering Hale and Dorr LLP. 

60 State Street 
 Boston, MA 02446 
 Attention: David E. Redlick 

Facsimile: 617-526-5000 
 Telephone: 617-526-6000 
 or to such other address as each party may designate for
itself by like notice. Any notification delivered to a party to this Agreement in accordance with this Section shall be valid notwithstanding any failure to deliver a copy thereof to a Person not party to this Agreement. 

11.3 Entire Agreement; Amendments. This Agreement, the Notes, and the other Loan Documents constitute the entire agreement
and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or
oral, with respect to the subject matter hereof or thereof (including Lender’s revised proposal letter dated October 12, 2011). None of the terms of this Agreement, the Notes or any of the other Loan Documents may be amended except by an
instrument executed by each of the parties hereto. 
 11.4 No Strict Construction. The parties hereto have
participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or
burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 11.5 No Waiver. The powers conferred upon Lender by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any
duty upon Lender to exercise any such powers. No omission or delay by Lender at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated,
shall be a waiver of any such right or remedy to which Lender is entitled, nor shall it in any way affect the right of Lender to enforce such provisions thereafter. 

11.6 Survival. All agreements, representations and warranties contained in this Agreement, the Notes and the other Loan
Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Lender and shall survive the execution and delivery of this Agreement and Section 6.3 and any provisions that, by their express terms are to survive
the expiration or other termination of this Agreement shall survive such expiration or termination. 

  
 26 

 11.7 Successors and Assigns. The provisions of this Agreement and the other
Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement, the Notes or any of the other Loan Documents without Lender’s express
prior written consent, and any such attempted assignment shall be void and of no effect. Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents to an Assignee (defined in Section 11.13) without prior
notice to Borrower or Borrower’s consent, and all of such rights shall inure to the benefit of Lender’s successors and assigns. 
 11.8 Governing Law. This Agreement, the Notes and the other Loan Documents have been negotiated and delivered to Lender in the Commonwealth of Massachusetts, and shall have been accepted by Lender in the
Commonwealth of Massachusetts. Payment to Lender by Borrower of the Secured Obligations is due in the Commonwealth of Massachusetts. This Agreement, the Notes and the other Loan Documents shall be governed by, and construed and enforced in
accordance with, the laws of the Commonwealth of Massachusetts, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

11.9 Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of
Section 11.10 is not applicable) arising in or under or related to this Agreement, the Notes or any of the other Loan Documents may be brought in any state or federal court located in the Commonwealth of Massachusetts. By execution and delivery
of this Agreement, each party hereto generally and unconditionally: (a) consents to exclusive personal jurisdiction in Suffolk County, Commonwealth of Massachusetts; (b) waives any objection as to jurisdiction or venue in the Business
Litigation Session of the Suffolk Superior Court, Suffolk County, Commonwealth of Massachusetts; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by
any judgment rendered thereby in connection with this Agreement, the Notes or the other Loan Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with
the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the
right of either party to bring proceedings in the courts of any other jurisdiction. 
 11.10 Mutual Waiver of
Jury Trial / Judicial Reference. 
 (a) Because disputes arising in connection with complex financial
transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a
judge applying such applicable laws. EACH OF BORROWER AND LENDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, 

  
 27 

 
COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST LENDER OR ITS ASSIGNEE OR BY LENDER OR ITS ASSIGNEE AGAINST BORROWER. This
waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender; Claims that arise out of or are in any way connected to the relationship between Borrower and Lender; and any Claims for damages, breach of
contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document. 
 11.11 Professional Fees. Borrower promises to pay Lender’s fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable attorneys fees, UCC searches, filing
costs, and other reasonable miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable attorneys’ and other reasonable professionals’ fees and expenses incurred by Lender after the Closing Date in connection with
or related to: (a) the Loan; (b) the administration, collection, or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents;
(e) the protection, preservation, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in
connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to
Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof. 

11.12 Confidentiality. Lender acknowledges that certain items of Collateral and information provided to Lender by Borrower
are confidential or proprietary information of Borrower, if and to the extent such information either (x) is marked as confidential, proprietary or secret by Borrower at the time of disclosure, or (y) should reasonably be understood to be
confidential, proprietary or secret (the “Confidential Information”). Accordingly, Lender agrees that any Confidential Information it may obtain in the course of acquiring, administering, perfecting or enforcing Lender’s security
interest in the Collateral or otherwise shall not be disclosed to any other person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Lender may disclose any such information:
(a) to its own directors, officers, employees, accountants, counsel and other professional advisors and to its controlled affiliates if Lender in its sole discretion determines that any such party should have access to such information in
connection with such party’s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this
paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public without any disclosure by
Lender or breach of this Section 11.12; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Lender; (d) if required or appropriate
in 

  
 28 

 
response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Lender’s counsel; (e) to comply with any legal requirement or
law applicable to Lender; (f) to the extent reasonably necessary in connection with the exercise of any right or remedy under any Loan Document, including Lender’s sale, lease, or other disposition of Collateral during the continuation of
an Event of Default; (g) to any participant or assignee of Lender or any prospective participant or assignee; provided, that such participant or assignee or prospective participant or assignee agrees in writing to be bound by this Section prior
to disclosure; or (h) otherwise with the prior written consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its affiliates or any guarantor under this
Agreement or the other Loan Documents. 
 11.13 Assignment of Rights. Borrower acknowledges and understands that
Lender may sell and assign all or part of its interest hereunder and under the Note(s) and Loan Documents (an “Assignment”) to any person or entity provided that (a) no such Assignment shall be made to a competitor of the Borrower,
and (b) Lender will not make any Assignment to a Person organized or resident outside the United States without Borrower’s consent which shall not be unreasonably withheld (such assignee, an “Assignee” or “assignee”).
After such assignment the term “Lender” as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Lender hereunder with respect to the interest so
assigned; but with respect to any such interest not so transferred, Lender shall retain all rights, powers and remedies hereby given. No such assignment by Lender shall relieve Borrower of any of its obligations hereunder. No such Assignment shall
release the Lender from its obligations to fund the Term Advance subject to the terms and conditions contained in Section 2.1 hereof. Lender agrees that in the event of any transfer by it of the Note(s), it will endorse thereon a notation as to
the portion of the principal of the Note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon. 

11.14 Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and
continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any
significant part of Borrower’s assets, or if any payment or transfer of Collateral is recovered from Lender. The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or
reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or
returned by, or is recovered from, Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or transfer of Collateral
had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or
documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Lender in Cash. 

  
 29 

 11.15 Counterparts. This Agreement and any amendments, waivers, consents or
supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the
same instrument. 
 11.16 No Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor
will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any person other than Lender and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all
provisions of the Loan Documents will be personal and solely between the Lender and the Borrower. 
 11.17
Publicity. Subject to applicable law, Lender may use Borrower’s name and logo, and include a brief description of the relationship between Borrower and Lender, in Lender’s marketing materials, provided that the Borrower shall have the
right to review such use prior to publication. 
 (SIGNATURES TO FOLLOW) 

  
 30 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and
Security Agreement as of the day and year first above written. 
  

			
	BORROWER:
	
	CONCERT PHARMACEUTICALS, INC.
		
	Signature:	 	/s/ Roger D. Tung
		 	  

		
	Print Name:	 	Roger D. Tung
		
	Title:	 	Chief Executive Officer

 Accepted in Boston, Massachussets: 

 

			
	LENDER:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	  

	Name:	 	  

	Its:	 	  

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and
Security Agreement as of the day and year first above written. 
  

							
		 		 	   BORROWER:
			
		 		 	   CONCERT PHARMACEUTICALS, INC.
				
		 		 	   Signature:	 	  

				
		 		 	   Print Name:	 	  

				
		 		 	   Title:	 	  

				
	Accepted in Boston, Massachussets:	 		 		 	

  

			
	LENDER:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	/s/ K. Nicholas Martitsch
		 	  

	Name:	 	 K. Nicholas Martitsch

	Its:	 	 Associate General Counsel

  
 31 

 Table of Exhibits and Schedules 

 

			
	Exhibit A:	  	Advance Request
		  	Attachment to Advance Request
		
	Exhibit B-1:	  	Term Note
		
	Exhibit C:	  	Name, Locations, and Other Information for Borrower
		
	Exhibit D:	  	Borrower’s Patents, Trademarks, Copyrights and Licenses
		
	Exhibit E:	  	Borrower’s Deposit Accounts and Investment Accounts
		
	Exhibit F:	  	Compliance Certificate
		
	Exhibit G:	  	Joinder Agreement
		
	Exhibit H:	  	ACH Debit Authorization Agreement
		
	Schedule 1	  	Subsidiaries
	Schedule 1A	  	Existing Permitted Indebtedness
	Schedule 1B	  	Existing Permitted Investments
	Schedule 1C	  	Existing Permitted Liens
	Schedule 5.3	  	Consents, Etc.
	Schedule 5.5	  	Actions Before Governmental Authorities
	Schedule 5.8	  	Tax Matters
	Schedule 5.9	  	Intellectual Property Claims
	Schedule 5.10	  	Intellectual Property
	Schedule 5.11	  	Borrower Products
	Schedule 5.14	  	Capitalization

  
 1 

 EXHIBIT A 
 ADVANCE REQUEST 
  

			
	To:	  	Date:                           
             , 201  

 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA 94301 
 Facsimile: 650-473-9194 

Attn: Janice Bourque 

CONCERT PHARMACEUTICALS, INC. (“Borrower”) hereby requests from Hercules Technology Growth Capital, Inc. (“Lender”) an Advance
in the amount of          Dollars ($        ) on
                    ,              (the “Advance Date”) pursuant to the Loan
and Security Agreement between Borrower and Lender (the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement. 

Please: 
  

									
	(a)	  	Issue a check payable to Borrower	  	  
	  	
				
		  	or	  		  	
				
	(b)	  	Wire Funds to Borrower’s account	  	  
	  	
				
		  	Bank:	  	  
	  	
		  	Address:	  	  
	  	
		  		  	  
	  	
		  	ABA Number:	  	  
	  	
		  	Account Number:	  	  
	  	
		  	Account Name:	  	  
	  	

 Borrower represents that the conditions precedent to the Advance set forth in the Agreement are satisfied and shall be
satisfied upon the making of such Advance, including but not limited to: (i) that no Material Adverse Effect has occurred and is continuing; (ii) No Material Adverse Effect has occurred and is continuing; (iii) that the
representations and warranties set forth in the Agreement are true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and
warranties expressly relate to an earlier date; (iv) that Borrower is in compliance in all material respects with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (v) that as of the
Advance Date, no fact or condition exists that constitutes (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default under the Loan Documents. Borrower understands and acknowledges that Lender has the right
to review the financial information supporting this representation and, based upon such review in its sole discretion, Lender may decline to fund the requested Advance if such representation is not true and correct in all material respects.

  
 2 

 Borrower hereby represents that the information described in Exhibit C to the Loan Agreement
have not changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request. 
 Borrower agrees to notify Lender promptly before the funding of the Loan if any of the matters which have been represented above shall not be true and correct on the Borrowing Date and if Lender has
received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true and correct as of the Advance Date. 

Executed as of                     ,
201  . 
  

			
	BORROWER:
	
	CONCERT PHARMACEUTICALS, INC.
		
	SIGNATURE:	 	  

 
			
	TITLE:	 	  

 
			
	PRINT NAME:	 	  

  
 3 

 ATTACHMENT TO ADVANCE REQUEST 

Dated:                     

 Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational status is as follows: 

 

			
	Name:	  	CONCERT PHARMACEUTICALS, INC.
		
	Type of organization:	  	Corporation
		
	State of organization:	  	Delaware
		
	Organization file number:	  	4141420

 Borrower hereby represents and warrants to Lender that the street addresses, cities, states and postal codes of its
current owned and leased locations are as follows: 

  
 4 

 EXHIBIT B-1 
 SECURED TERM PROMISSORY NOTE 
  

			
	$        	  	Advance Date:                     ,
201  
		
		  	Maturity Date: July 1, 2015

 FOR VALUE RECEIVED, CONCERT PHARMACEUTICALS, INC., a Delaware corporation (the
“Borrower”) hereby promises to pay to the order of Hercules Technology Growth Capital, Inc. or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or such other place of payment as the
holder of this Secured Term Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America, the principal amount of         
($        ) or such other principal amount as Lender has advanced to Borrower, together with interest at a floating rate equal to the greater of (a) 8.50% per annum and (b) 8.50% plus the United
States Prime Rate as reported in The Wall Street Journal minus 5.25%, not in any case to exceed 11.0% per annum, based upon a year consisting of 360 days, with interest computed daily based on the actual number of days in each month.

 This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and
Security Agreement dated December     , 2011, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is
entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in
accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall constitute a default under this
Promissory Note. 
 Borrower waives presentment and demand for payment, notice of dishonor, protest and notice of protest under
the UCC or any applicable law. Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated and delivered to Lender
and is payable in the Commonwealth of Massachusetts. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the Commonwealth of Massachusetts, excluding any conflicts of law rules or principles that
would cause the application of the laws of any other jurisdiction. 
  

							
	BORROWER:	 		 	CONCERT PHARMACEUTICALS, INC.
				
		 		 	By:	 	  

				
		 		 	Title:	 	  

 EXHIBIT C 
 NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER 
 1. Borrower
represents and warrants to Lender that Borrower’s current name and organizational status as of the Closing Date is as follows: 
  

			
	Name:	  	CONCERT PHARMACEUTICALS, INC.
		
	Type of organization:	  	Corporation
		
	State of organization:	  	Delaware
		
	Organization file number:	  	4141420

 2. Borrower represents and warrants to Lender that for five (5) years prior to the Closing Date,
Borrower did not do business under any other name or organization or form except the following: 
 Name: Concert Pharmaceuticals,
Inc. 
 Used during dates of: Five (5) years prior to the Closing 

Type of Organization: Corporation 
 State of organization: Delaware 
 Organization file Number: 4141420 

Borrower’s fiscal year ends on: December 31 
 Borrower’s federal employer tax identification number is: 20-4839882 
 3.
Borrower represents and warrants to Lender that its chief executive office is located at 99 Hayden Avenue, Suite 400 & 500, Lexington, MA 02421. 

 EXHIBIT D 
 BORROWER’S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES 
 See attached. 

							
	 	  	Title	  	Application Number	  	Filing Date
				
	1	  	4-Hydroxybutyric Acid Analogs	  		  	
		  	 United States of America
	  	61/442451	  	February 14, 2011
		  	 United States of America
	  	61/484296	  	May 10, 2011
		  	 Canada
	  	2740247	  	May 13, 2011
		  	 Australia
	  	2011200745	  	February 22, 2011
		  	 Canada
	  	2732479	  	February 23, 2011
		  	 Australia
	  	2011202741	  	June 8, 2011
				
	2	  	4-Hydroxybutyric Acid Analogs	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/031981	  	April 22, 2010
		  	 Australia
	  	 2010239244
	  	October 23, 2011
		  	 European Patent Convention
	  	10716196	  	October 23, 2011
		  	 United States of America
	  	 13/265609
	  	October 23, 2011
		  	 Canada
	  	NEW APPLICATION	  	October 23, 2011
		  	 India
	  	 8456/DELNP/2011
	  	October 23, 2011
				
	3	  	Alpha 1A-adrenoceptor antagonists	  		  	
		  	 United States of America
	  	12/072,501	  	February 26, 2008
		  	 United States of America
	  	12/550864	  	February 26, 2008
		  	 United States of America
	  	13/189080	  	July 22, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2008/002513	  	February 26, 2008
		  	 European Patent Convention
	  	8726096.4	  	February 26, 2008
				
	4	  	Analogues of cilostazol	  		  	
		  	 United States of America
	  	12/150107	  	April 24, 2008
		  	 United States of America
	  	12/644758	  	December 22, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2008/005301	  	April 24, 2008
		  	 European Patent Convention
	  	8743256.3	  	April 24, 2008
				
	5	  	Carbamoylpyridone derivatives	  		  	
		  	 United States of America
	  	61/481977	  	May 3, 2011
				
	6	  	Derivatives of dimethylcurcumin	  		  	
		  	 United States of America
	  	13/049481	  	March 16, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2011/028631	  	March 16, 2011
				
	7	  	Deuterated 2-amino-3-hydroxypropanoic acid derivatives	  		  	
		  	 United States of America
	  	13/119318	  	March 16, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/057001	  	September 15, 2009
		  	 European Patent Convention
	  	9792561.4	  	September 15, 2009
				
	8	  	Deuterated Benzo[D][1,3]-dioxol derivatives	  		  	
		  	 United States of America
	  	12/688466	  	January 15, 2010

  
 Page 1 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	9	  	Deuterated CFTR potentiators	  		  	
		  	 United States of America
	  	61/487497	  	May 18, 2011
				
	10	  	Deuterated fingolimod	  		  	
		  	 United States of America
	  	12/290645	  	October 31, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/012390	  	October 31, 2008
		  	 European Patent Convention
	  	8847117.2	  	October 31, 2008
		  	 Hong Kong
	  	11101551.6	  	
		  	 Japan
	  	2010-532064	  	October 31, 2008
		  	 United States of America
	  	13/311171	  	05-Dec-2011
				
	11	  	Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/038577	  	June 15, 2010
		  	 Australia
	  	instructions to file sent	  	December 6, 2011
		  	 Brazil
	  	instructions to file sent	  	December 6, 2011
		  	 Canada
	  	instructions to file sent	  	December 6, 2011
		  	 China (People’s Republic)
	  	201010620532.7	  	December 22, 2010
		  	 Eurasian Patent Organization
	  	instructions to file sent	  	December 6, 2011
		  	 European Patent Convention
	  	instructions to file sent	  	December 6, 2011
		  	 India
	  	instructions to file sent	  	December 6, 2011
		  	 Japan
	  	instructions to file sent	  	December 6, 2011
		  	 Korea, Republic of
	  	10-2010-0132933	  	December 22, 2010
				
	12	  	Substituted isoindoline-1,3-dione derivatives	  		  	
		  	 United States of America
	  	12/816295	  	June 15, 2010
		  	 Korea, Republic of
	  	10-2010-0132933	  	December 22, 2010
		  	 China (People’s Republic)
	  	2.01011E+11	  	December 22, 2010
				
	13	  	Deuterated pyridinones	  		  	
		  	 United States of America
	  	13/132784	  	December 3, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/066606	  	December 3, 2009
				
	14	  	Fluorinated diaryl urea derivatives	  		  	
		  	 United States of America
	  	13/320646	  	15-Nov-2011
		  	 Patent Cooperation Treaty
	  	PCT/US2010/035655	  	May 20, 2010
				
	15	  	Fluorouracil derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/026436	  	February 28, 2011
				
	16	  	Method of utilizing recycled deuterium oxide in the synthesis of deuterated compounds	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/050134	  	September 1, 2011

  
 Page 2 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	17	  	Niacin prodrugs and deuterated versions thereof	  		  	
		  	 United States of America
	  	12/948484	  	November 17, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/057051	  	November 17, 2010
				
	18	  	Novel benzo[D][1,3]-dioxol derivatives	  		  	
				
		  	 Patent Cooperation Treaty
	  	PCT/US2006/029599	  	July 28, 2006
		  	 Australia
	  	2006275595	  	July 28, 2006
		  	 Brazil
	  	PI0615973-7	  	July 28, 2006
		  	 Canada
	  	2616383	  	July 28, 2006
		  	 China (People’s Republic)
	  	2.0068E+11	  	July 28, 2006
		  	 Eurasian Patent Organization
	  	200800490	  	July 28, 2006
		  	 European Patent Convention
	  	6813250.5	  	July 28, 2006
		  	 Hong Kong
	  	8111437	  	July 28, 2006
		  	 India
	  	607/DELNP/2008	  	July 28, 2006
		  	 Japan
	  	2008-524227	  	July 28, 2006
		  	 Korea, Republic of
	  	10-2008-7004867	  	July 28, 2006
		  	 Mexico
	  	MX/a/2008/001193	  	July 28, 2006
		  	 Philippines
	  	1-2008-500121	  	July 28, 2006
		  	 South Africa
	  	2008/00785	  	July 28, 2006
		  	 United States of America
	  	11/704554	  	February 8, 2007
				
	19	  	Novel tetrahydro-1H-pyrido[4,3-B]indoles	  		  	
		  	 United States of America
	  	12/625059	  	November 24, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/065872	  	November 25, 2009
				
	20	  	Oxazolidinone derivatives and methods of use	  		  	
		  	 United States of America
	  	12/214260	  	June 17, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2007/022516	  	October 23, 2007
		  	 Hong Kong
	  	10102539.2	  	October 23, 2007
		  	 Japan
	  	2009-533406	  	October 23, 2007
				
	21	  	Polymorphs of (S)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1H-purine-2,6(3H,7H)-dione	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/050229	  	September 1, 2011
				
	22	  	Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/050138	  	September 1, 2011

  
 Page 3 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	23	  	Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/050139	  	September 1, 2011
				
	24	  	Prostacyclin analogs	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2009/003801	  	June 26, 2009
		  	 United States of America
	  	13/001543	  	March 31, 2011
				
	25	  	Prostacyclin analogs	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2007/026264	  	December 21, 2007
		  	 United States of America
	  	12/520493	  	December 21, 2007
		  	 United States of America
	  	12/489425	  	June 22, 2009
		  	 Japan
	  	2009-542961	  	December 21, 2007
		  	 Australia
	  	2007338701	  	December 21, 2007
		  	 Brazil
	  	PI0719463-3	  	December 21, 2007
		  	 Canada
	  	2672904	  	December 21, 2007
		  	 China (People’s Republic)
	  	2.0078E+11	  	December 21, 2007
		  	 Eurasian Patent Organization
	  	200900862	  	December 21, 2007
		  	 European Patent Convention
	  	7863238.7	  	December 21, 2007
		  	 India
	  	4730/DELNP/2009	  	December 21, 2007
		  	 Korea, Republic of
	  	10-2009-7015336	  	December 21, 2007
		  	 Mexico
	  	MX/a/2009/006692	  	December 21, 2007
		  	 South Africa
	  	2009/04722	  	December 21, 2007
				
	26	  	Prostacyclin analogs	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/040891	  	July 2, 2010
				
	27	  	Pyrazinoisoquinoline compounds	  		  	
		  	 United States of America
	  	61/449312	  	March 4, 2011
				
	28	  	Pyrazinoisoquinoline compounds	  		  	
		  	 United States of America
	  	61/210279	  	March 17, 2009
		  	 United States of America
	  	13/256787	  	September 15, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2010/027476	  	March 16, 2010
		  	 African Union Territories (OAPI)
	  	NEW APPLICATION	  	September 15, 2011
		  	 Brazil
	  	NEW APPLICATION	  	September 19, 2011
		  	 European Patent Convention
	  	10709147.2	  	October 14, 2011
		  	 India
	  	7022/DELNP/2011	  	September 14, 2011
		  	 African Regional Industrial Property Organization
	  	 AP/P/2011/005932
	  	
				
	29	  	Pyridineamine derivatives	  		  	
		  	 United States of America
	  	13/120455	  	August 26, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/058212	  	September 24, 2009

  
 Page 4 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	30	  	Pyridineamine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/011417	  	October 2, 2008
		  	 Hong Kong
	  	11100851.5	  	October 2, 2008
		  	 Japan
	  	2010-527991	  	October 2, 2008
				
	31	  	Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/047557	  	September 1, 2010
				
	32	  	Substituted dioxopiperidinyl phthalimide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US11/064409	  	December 12, 2011
				
	33	  	Substituted dioxopiperidinyl phthalimide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US11/064238	  	December 9, 2011
				
	34	  	Substituted diphenylpyrazine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/044704	  	August 6, 2010
				
	35	  	Substituted oxazolidinone derivatives	  		  	
		  	 United States of America
	  	12/228662	  	August 14, 2008
		  	 United States of America
	  	13/189003	  	July 22, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2008/009704	  	August 14, 2008
		  	 China (People’s Republic)
	  	200880107169.X	  	August 14, 2008
		  	 European Patent Convention
	  	8795304.8	  	August 14, 2008
		  	 Japan
	  	2010-521032	  	August 14, 2008
				
	36	  	Substituted xanthine derivatives	  		  	
		  	 United States of America
	  	12/380579	  	February 27, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/001305	  	February 27, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/001294	  	February 27, 2009
		  	 Argentina
	  	P090103281	  	August 26, 2009
		  	 Australia
	  	2009217680	  	February 27, 2009
		  	 Brazil
	  	PI0908107-0	  	February 27, 2009
		  	 Canada
	  	2716788	  	February 27, 2009
		  	 China (People’s Republic)
	  		  	February 27, 2009
		  	 Eurasian Patent Organization
	  	201001391	  	February 27, 2009
		  	 European Patent Convention
	  	9715566.7	  	February 27, 2009
		  	 Hong Kong
	  	11104595.8	  	May 9, 2011
		  	 India
	  	6533/DELNP/2010	  	February 27, 2009
		  	 Japan
	  	2010-548745	  	February 27, 2009
		  	 Korea, Republic of
	  	10-2010-7021407	  	February 27, 2009
		  	 Mexico
	  	MX/a/2010/009300	  	February 27, 2009
		  	 Pakistan
	  	787/2009	  	August 25, 2009
		  	 South Africa
	  	2010/06104	  	February 27, 2009
		  	 Taiwan
	  	98128631	  	August 26, 2009
		  	 Venezuela
	  	2009-001574	  	August 25, 2009

  
 Page 5 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	37	  	Pharmaceutically acceptable salt of a substituted oxo(or hydroxy)hexyl-1H-purine-2,6(3H,7H)-dione compound	  		  	
				
		  	 Pakistan
	  	390/2010	  	August 25, 2009
				
	38	  	Substituted xanthine derivatives	  		  	
		  	 United States of America
	  	12/874049	  	September 1, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/047574	  	September 1, 2010
				
	39	  	Substituted xanthine derivatives	  		  	
		  	 United States of America
	  	12/873991	  	September 1, 2010
		  	 United States of America
	  	12/874783	  	September 2, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/047708	  	September 2, 2010
				
	40	  	Substituted xanthine derivatives	  		  	
		  	 Hong Kong
	  	11104593	  	May 9, 2011
		  	 Philippines
	  	1-2010-501961	  	February 27, 2009
		  	 Japan
	  	2010-548747	  	February 27, 2009
		  	 European Patent Convention
	  	9714926.4	  	February 27, 2009
				
	41	  	Substituted xanthine derivatives	  		  	
		  	 United States of America
	  	61/509343	  	July 19, 2011
				
	42	  	Synthesis of deuterated catechols and benzo[D][1,3] dioxoles and derivatives thereof	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/010643	  	September 12, 2008
		  	 Australia
	  	2008299921	  	September 12, 2008
		  	 Canada
	  	2698808	  	September 12, 2008
		  	 China (People’s Republic)
	  	2.0088E+11	  	September 12, 2008
		  	 European Patent Convention
	  	8830527.1	  	September 12, 2008
		  	 Hong Kong
	  	10112245.6	  	December 30, 2010
		  	 India
	  	2015/DELNP/2010	  	September 12, 2008
		  	 Japan
	  	2010-524866	  	September 12, 2008
		  	 Mexico
	  	MX/a/2010/002692	  	September 12, 2008
		  	 United States of America
	  	12/283621	  	September 12, 2008
				
	43	  	Synthesis of deuterated morpholine derivatives	  		  	
		  	 United States of America
	  	12/456507	  	June 17, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/003628	  	June 17, 2009

  
 Page 6 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	44	  	Substituted dioxopiperidinyl phthalimide derivatives	  		  	
		  	 United States of America
	  	13/107873	  	May 13, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2011/045629	  	July 27, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/006105	  	November 13, 2009
		  	 Australia
	  	2009314568	  	May 17, 2011
		  	 Brazil
	  	PI0915267-9	  	May 12, 2011
		  	 Canada
	  	2743902	  	May 13, 2011
		  	 China (People’s Republic)
	  	2.0098E+11	  	November 13, 2009
		  	 Eurasian Patent Organization
	  	201100750	  	June 10, 2011
		  	 European Patent Convention
	  	9826438.5	  	June 9, 2011
		  	 India
	  	1038/MUMNP/2011	  	May 23, 2011
		  	 Japan
	  	2011-536328	  	May 13, 2011
		  	 Korea, Republic of
	  	10-2011-7013575	  	June 14, 2011
		  	 Mexico
	  	MX/a/2011/005112	  	May 13, 2011
		  	 Philippines
	  	1-2011-500901	  	November 13, 2009
		  	 South Africa
	  	2011/04361	  	June 10, 2011
				
	45	  	Azapeptide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/007331	  	June 12, 2008
		  	 European Patent Convention
	  	08252023.0	  	June 12, 2008
		  	 Argentina
	  	P080102501	  	June 12, 2008
		  	 Pakistan
	  	6842008	  	June 12, 2008
		  	 Taiwan
	  	97122018	  	June 12, 2008
		  	 Venezuela
	  	2008001156	  	June 12, 2008
		  	 Hong Kong
	  	09105433.5	  	June 17, 2009
		  	 European Patent Convention
	  	09075359.1	  	June 12, 2008
		  	 Australia
	  	2008267048	  	June 12, 2008
		  	 Brazil
	  	PI08139113	  	June 12, 2008
		  	 Canada
	  	2692028	  	June 12, 2008
		  	 China (People’s Republic)
	  	200880021601.3	  	June 12, 2008
		  	 Colombia
	  	09141805	  	June 12, 2008
		  	 India
	  	8182DELNP2009	  	June 12, 2008
		  	 Japan
	  	2010512186	  	June 12, 2008
		  	 Mexico
	  	MXa2009013565	  	June 12, 2008
		  	 South Africa
	  	200909079	  	June 12, 2008
		  	 Korea, Republic of
	  	1020107000675	  	June 12, 2008
		  	 Switzerland
	  	08252023.0	  	June 12, 2008
		  	 Germany
	  	08252023.0	  	June 12, 2008
		  	 Spain
	  	08252023.0	  	June 12, 2008
		  	 France
	  	08252023.0	  	June 12, 2008
		  	 United Kingdom
	  	08252023.0	  	June 12, 2008
		  	 Italy
	  	08252023.0	  	June 12, 2008
		  	 Hong Kong
	  	10104316.7	  	April 30, 2010
		  	 United States of America
	  	12/755,184	  	April 6, 2010
		  	 European Patent Convention
	  	11155667.6	  	June 12, 2008
		  	 Hong Kong
	  	11109198.8	  	August 31, 2011
		  	 China (People’s Republic)
	  	 2.0111E+11
	  	June 12, 2008
		  	 Brazil
	  	(divisional) instructions to file sent	  	

  
 Page 7 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	46	  	4-oxoquinoline derivatives	  		  	
		  	 United States of America
	  	12/283,620	  	September 12, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/010662	  	September 12, 2008
		  	 Australia
	  	2008299931	  	September 12, 2008
		  	 Canada
	  	2698825	  	September 12, 2008
		  	 European Patent Convention
	  	08830735.0	  	September 12, 2008
		  	 India
	  	2377DELNP2010	  	September 12, 2008
		  	 Mexico
	  	MXA2010002679	  	September 12, 2008
		  	 United States of America
	  	13/153,952	  	June 6, 2011
				
	47	  	Deuterated darunavir	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/012079	  	October 24, 2008
		  	 United States of America
	  	12/387,327	  	April 28, 2009
		  	 Australia
	  	2008317375	  	October 24, 2008
		  	 Canada
	  	2703591	  	October 24, 2008
		  	 European Patent Convention
	  	08843302.4	  	October 24, 2008
				
	48	  	Peptides for the treatment of HCV infections	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/012949	  	November 20, 2008
		  	 European Patent Convention
	  	08851195.1	  	November 20, 2008
		  	 Japan
	  	2010534960	  	November 20, 2008
		  	 Hong Kong
	  	11101960.1	  	February 28, 2011
				
	49	  	Endothelin receptor antagonists	  		  	
		  	 United States of America
	  	12/008,698	  	January 11, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/000384	  	January 11, 2008
		  	 United States of America
	  	12/460,575	  	July 20, 2009
				
	50	  	Selective endothelin type-A antagonists	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2008/001358	  	February 1, 2008
		  	 European Patent Convention
	  	8713376.5	  	February 1, 2008
				
	51	  	Deuterated piperazine derivatives as anti-anginal compounds	  		  	
		  	 United States of America
	  	12/075,107	  	March 7, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/003183	  	March 7, 2008
		  	 European Patent Convention
	  	08726679.7	  	March 7, 2008
		  	 Japan
	  	2009552765	  	March 7, 2008
		  	 Belgium
	  	08726679.7	  	March 7, 2008
		  	 France
	  	08726679.7	  	March 7, 2008
		  	 Germany
	  	08726679.7	  	March 7, 2008
		  	 United Kingdom
	  	08726679.7	  	March 7, 2008
		  	 Italy
	  	08726679.7	  	March 7, 2008
		  	 Spain
	  	08726679.7	  	March 7, 2008
		  	 Switzerland
	  	08726679.7	  	March 7, 2008

  
 Page 8 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	52	  	Tricyclic benzo[5,6]cyclonepta[1, 2- B]pyridine derivatives and uses thereof	  		  	
				
		  	 Patent Cooperation Treaty
	  	PCT/US2009/002372	  	April 16, 2009
		  	 United States of America
	  	12/937,933	  	April 16, 2009
				
	53	  	Piperazine derivatives	  		  	
		  	 United States of America
	  	12/386,492	  	April 17, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/002424	  	April 17, 2009
		  	 United States of America
	  	12/603,380	  	October 21, 2009
				
	54	  	Xanthenone-4-acetic acid derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2009/060996	  	October 16, 2009
		  	 United States of America
	  	13/124,626	  	October 16, 2009
				
	55	  	Hydroxyethlamino sulfonamide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2009/005773	  	October 23, 2009
		  	 United States of America
	  	13/125,464	  	October 23, 2009
		  	 European Patent Convention
	  	09822333.2	  	October 23, 2009
				
	56	  	Hydroxyethylamino sulfonamide derivatives	  		  	
		  	 United States of America
	  	12/771,551	  	April 30, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/033206	  	April 30, 2010
				
	57	  	Deuterium modified benzimidazoles	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/034962	  	May 14, 2010
		  	 United States of America
	  	13/320,653	  	November 15, 2011
				
	58	  	Peptides for the treatment of HCV infections	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/036682	  	May 28, 2010
		  	 United States of America
	  	13/321,785	  	November 21, 2011
				
	59	  	Aminoquinoline derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/021715	  	January 19, 2011
				
	60	  	Tetrahydroisoquinoline derivatives	  		  	
		  	 United States of America
	  	12/338,754	  	December 18, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/087477	  	December 18, 2008
		  	 European Patent Convention
	  	08862459.8	  	December 18, 2008
				
	61	  	Inhibitors of cholesterol ester transfer protein	  		  	
		  	 United States of America
	  	12/049,074	  	March 14, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/003449	  	March 14, 2008
		  	 Canada
	  	2681628	  	March 14, 2008
		  	 European Patent Convention
	  	08742105.3	  	March 14, 2008
		  	 Hong Kong
	  	10105723.1	  	June 9, 2010

  
 Page 9 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	62	  	Synthetic triterpenoid derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/049163	  	August 25, 2011
				
	63	  	Atazanavir metabolite derivatives	  		  	
		  	 United States of America
	  	61/495,877	  	June 10, 2011
				
	64	  	Atazanavir metabolite derivatives	  		  	
		  	 United States of America
	  	61/495,870	  	June 10, 2011
				
	65	  	Deuterated 18-methoxycoronadidine	  		  	
		  	 United States of America
	  	61/505,361	  	July 7, 2011
				
	66	  	Substituted diphenylpyrazine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/044704	  	August 6, 2010
				
	67	  	Niacin prodrugs and deuterated versions thereof	  		  	
		  	 United States of America
	  	12/948,484	  	November 17, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2010/057051	  	November 17, 2010
				
	68	  	Pharmaceutical calcimimetics	  		  	
		  	 United States of America
	  	12/975,464	  	December 22, 2010
		  	 Canada
	  	2701638	  	April 1, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/059023	  	April 1, 2008
				
	69	  	1,2-benzisoxazol-3-yl compounds	  		  	
		  	 United States of America
	  	12/102,164	  	April 14, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/060210	  	April 14, 2008
				
	70	  	Naphthyl(ethyl)acetamides	  		  	
		  	 United States of America
	  	12/112,722	  	April 30, 2008
		  	 Canada
	  	2685924	  	April 30, 2008
		  	 European Patent Convention
	  	08769252.1	  	April 30, 2008
		  	 Japan
	  	2009-551067	  	April 30, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/062039	  	April 30, 2008
				
	71	  	Morphinan compounds	  		  	
		  	 United States of America
	  	12/112,936	  	April 30, 2008
		  	 United States of America
	  	13/118,912	  	May 31, 2011
		  	 United States of America
	  	13/118,935	  	May 31, 2011
		  	 Australia
	  	2008247818	  	April 30, 2008
		  	 Australia
	  	(divisional) instructions to file sent	  	
		  	 Brazil
	  	PI0811478-1	  	April 30, 2008
		  	 Canada
	  	2685723	  	April 30, 2008

  
 Page 10 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
		  	 China (People’s Republic)
	  	200880017768.2	  	April 30, 2008
		  	 European Patent Convention
	  	08747238.7	  	April 30, 2008
		  	 European Patent Convention
	  	11000763.0	  	April 30, 2008
		  	 European Patent Convention
	  	11000764.8	  	April 30, 2008
		  	 Hong Kong
	  	1010707.6	  	August 9, 2010
		  	 Hong Kong
	  	11109618.0	  	September 12, 2011
		  	 Hong Kong
	  	11109620.6	  	September 12, 2011
		  	 India
	  	7533/DELNP/2009	  	April 30, 2008
		  	 Japan
	  	2010-506617	  	April 30, 2008
		  	 Mexico
	  	2009/011958	  	April 30, 2008
		  	 Mexico
	  	MX/a/2011/010560	  	October 6, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2008/062089	  	April 30, 2008
				
	72	  	N-phenyl-2-pyrimidineamine derivatives	  		  	
		  	 United States of America
	  	12/539,091	  	August 11, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US2009/053384	  	August 11, 2009
				
	73	  	Deuterated etravirine	  		  	
		  	 United States of America
	  	12/288,186	  	October 17, 2008
		  	 European Patent Convention
	  	08839230.3	  	October 17, 2008
		  	 Hong Kong
	  	11101126.2	  	October 17, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/011856	  	October 17, 2008
				
	74	  	Deuterated morpholinyl compounds	  		  	
		  	 United States of America
	  	12/106,127	  	April 18, 2008
		  	 Australia
	  	2008242703	  	April 18, 2008
		  	 Brazil
	  	P10810362-3	  	April 18, 2008
		  	 Canada
	  	2686545	  	April 18, 2008
		  	 China (People’s Republic)
	  	200880012551.2	  	April 18, 2008
		  	 European Patent Convention
	  	08746315.4	  	April 18, 2008
		  	 India
	  	7500/DELNP/2009	  	April 18, 2008
		  	 Japan
	  	2010-504289	  	April 18, 2008
		  	 Japan
	  	2011-18410	  	January 31, 2011
		  	 South Korea
	  	10-2009-7024119	  	April 18, 2008
		  	 South Korea
	  	10-2010-7020029	  	September 8, 2010
		  	 Patent Cooperation Treaty
	  	PCT/US2008/060877	  	April 18, 2008
				
	75	  	Deuterated 2-propylpentanoic acid compounds	  		  	
		  	 European Patent Convention
	  	09744570.4	  	October 28, 2009
		  	 United States of America
	  	13/126,384	  	April 27, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/062397	  	October 28, 2009
				
	76	  	Novel pyrimidinecarboxamide derivatives	  		  	
		  	 United States of America
	  	12/169,367	  	July 8, 2008
		  	 United States of America
	  	12/712,399	  	February 25, 2010
		  	 Canada
	  	2702317	  	July 8, 2008
		  	 Patent Cooperation Treaty
	  	PCT/US2008/069425	  	July 8, 2008

  
 Page 11 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	77	  	Deuterated tizanidine	  		  	
		  	 United States of America
	  	12/993,530	  	February 10, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/045245	  	May 27, 2009
				
	78	  	Analogs of d-dextromethorphan	  		  	
		  	 Australia
	  	2009293123	  	September 18, 2009
		  	 Brazil
	  	PI0918760-0	  	September 18, 2009
		  	 Canada
	  	2737811	  	September 18, 2009
		  	 China
	  	200980142670.4	  	September 18, 2009
		  	 Eurasia
	  	201170473	  	September 18, 2009
		  	 European Patent Convention
	  	09792714.9	  	September 18, 2009
		  	 European Patent Convention
	  	11188848.3	  	September 18, 2009
		  	 Hong Kong
	  	N/A	  	September 18, 2009
		  	 India
	  	2116/DELNP/2011	  	September 18, 2009
		  	 India
	  	(divisional) instructions to file sent	  	
		  	 Japan
	  	2011-527994	  	September 18, 2009
		  	 South Korea
	  	10-2011-7008130	  	September 18, 2009
		  	 South Korea
	  	10-2011-7027474	  	November 18, 2011
		  	 Mexico
	  	N/MX/a/2011/002994	  	September 18, 2009
		  	 Philipines
	  	1-2011-500574	  	September 18, 2009
		  	 United States of America
	  	13/119,905	  	July 1, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/057476	  	September 18, 2009
		  	 South Africa
	  	2011/02113	  	September 18, 2009
				
	79	  	Morphinan compounds	  		  	
		  	 United States of America
	  	13/155,827	  	June 8, 2011
				
	80	  	Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain
injury	  		  	
		  	 European Patent Convention
	  	09744582.9	  	October 30, 2009
		  	 European Patent Convention
	  	11180603.0	  	October 30, 2009
		  	 United States of America
	  	13/126,397	  	April 27, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/062783	  	October 30, 2009
				
	81	  	Methods for the treatment of neurological diseases and conditions	  		  	
		  	 European Patent Convention
	  	09744581.1	  	October 30, 2009
		  	 European Patent Convention
	  	11180608.9	  	October 30, 2009
		  	 United States of America
	  	13/126,447	  	April 27, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2009/062779	  	October 30, 2009

  
 Page 12 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	82	  	Substituted azaindoles	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/056447	  	November 12, 2010
				
	83	  	Pyrimidine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/025472	  	February 18, 2011
				
	84	  	Deuterated tetrahydronaphthalene derivatives	  		  	
		  	 United States of America
	  	13/038,533	  	March 2, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2011/026787	  	March 2, 2011
				
	85	  	Tetrahydronaphthalene derivatives	  		  	
		  	 United States of America
	  	13/227,047	  	September 7, 2011
				
	86	  	Novel pyrimidinecarboxamide derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/043872	  	July 13, 2011
				
	87	  	Substituted azaindoles	  		  	
		  	 United States of America
	  	13/230,970	  	September 13, 2011
		  	 Patent Cooperation Treaty
	  	PCT/US2011/051297	  	September 13, 2011
				
	88	  	Substituted tetracyclines	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2011/060310	  	November 11, 2011
				
	89	  	Deuterated chlophedianol	  		  	
		  	 United States of America
	  	61/436,634	  	January 27, 2011
				
	90	  	2-amino-naphthyridine derivatives	  		  	
		  	 United States of America
	  	61/446,733	  	February 25, 2011
				
	91	  	Deuterated prelandenant	  		  	
		  	 United States of America
	  	61/466,310	  	March 22, 2011
				
	92	  	Deuterated N-butyl bumetanide	  		  	
		  	 United States of America
	  	61/484,412	  	May 10, 2011
				
	93	  	Synthetic triterpenoid derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	US11/34984	  	May 3, 2011
				
	94	  	[5,6]-dihydro-2H-pyran-2-one derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	US11/40731	  	June 16, 2011
				
	95	  	Derivatives of pyrazole-substituted amino-heteroaryl compounds	  		  	
		  	 United States of America
	  	61/448,887	  	March 3, 2011

  
 Page 13 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	96	  	Novel pharmaceutical compounds	  		  	
		  	 Australia
	  	2006275702	  	July 28, 2006
		  	 China (People’s Republic)
	  	200680036393.50	  	July 28, 2006
		  	 Japan
	  	2008-524206	  	July 28, 2006
		  	 United States of America
	  	11/704,555	  	February 8, 2007
		  	 United States of America
	  	12/954,591	  	November 24, 2010
		  	 European Patent Convention
	  	11155798.9	  	July 28, 2006
				
	97	  	Biphenyl-pyrazolecarboxamide compounds	  		  	
		  	 United States of America
	  	11/521,926	  	September 14, 2006
				
	98	  	Novel 1,2,3,4-tetrahydroquinoline derivatives	  		  	
		  	 United States of America
	  	12/296,927	  	September 30, 2009
				
	99	  	3-(dihydro-1H-pyrazolo[4,3-D]pyrimidin-5-YL)-4-propoxybenzenesulfonamide derivatives and methods of use	  		  	
		  	 Korea, Republic of
	  	10-2009-7010321	  	October 22, 2007
		  	 United States of America
	  	11/876,754	  	October 22, 2007
		  	 Japan
	  	2009-533595	  	October 22, 2007
		  	 India
	  	868/MUMNP/2009	  	October 22, 2007
		  	 Mexico
	  	MX/a/2009/003941	  	October 22, 2007
				
	100	  	Dibenzothiazepine derivatives	  		  	
		  	 United States of America
	  	12/425,957	  	April 17, 2009
				
	101	  	Triazolyl tropane derivatives	  		  	
		  	 United States of America
	  	11/941,925	  	November 16, 2007
		  	 United States of America
	  	13/044,534	  	March 9, 2011
				
	102	  	Heterocyclic kinase inhibitors	  		  	
		  	 European Patent Convention
	  	8859849.5	  	December 9, 2008
		  	 Hong Kong
	  	11102019	  	December 9, 2008
		  	 United States of America
	  	12/331,431	  	December 9, 2008
				
	103	  	Vandetanib derivatives	  		  	
		  	 United States of America
	  	12/864,219	  	November 16, 2010
				
	104	  	Derivatives of gefitinib	  		  	
		  	 European Patent Convention
	  	9703515.8	  	January 22, 2009
		  	 Hong Kong
	  	10111408.1	  	January 22, 2009
		  	 United States of America
	  	12/358,238	  	January 22, 2009
		  	 Japan
	  	2010-544356	  	January 22, 2009
		  	 United States of America
	  	12/946,856	  	November 15, 2010

  
 Page 14 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
	105	  	Quinazoline derivatives and methods of treatment	  	11/957,442	  	December 15, 2007
		  	 United States of America
	  	12/694,249	  	January 26, 2010
				
	106	  	Derivatives of 3-(2-hydroxy-5-methyphenyl)-N,N-diisopropyl-3- phenylpropylamine and methods of use thereof	  		  	
		  	 China (People’s Republic)
	  	200980121626.50	  	April 9, 2009
		  	 Korea, Republic of
	  	10-2010-7025129	  	April 9, 2009
		  	 United States of America
	  	12/937,262	  	January 26, 2011
		  	 Japan
	  	2011-504185	  	April 9, 2009
				
	107	  	Substituted triazolo-pyridazine derivatives	  		  	
		  	 Canada
	  	2735549	  	August 28, 2009
		  	 European Patent Convention
	  	9810685.9	  	August 28, 2009
		  	 Eurasian Patent Organization
	  	201100409	  	August 28, 2009
		  	 Australia
	  	2009285533	  	August 28, 2009
		  	 Brazil
	  	PI0912928-6	  	August 28, 2009
		  	 China (People’s Republic)
	  	200980140350.50	  	August 28, 2009
		  	 Korea, Republic of
	  	10-2011-7006632	  	August 28, 2009
		  	 Philippines
	  	1-2011-500500	  	August 28, 2009
		  	 South Africa
	  	2011/02123	  	August 28, 2009
		  	 India
	  	438/MUMNP/2011	  	August 28, 2009
		  	 Japan
	  	2011-525250	  	August 28, 2009
		  	 Mexico
	  	MX/a/2011/002278	  	August 28, 2009
		  	 United States of America
	  	12/550,346	  	February 4, 2009
		  	 United States of America
	  	13/174,662	  	June 30, 2011
				
	108	  	3-(dihydro-1H-pyrazolo[4,3-D]pyrimidin-5-YL)-4-propoxybenzenesulfonamide derivatives and methods of use	  		  	
				
		  	 United States of America
	  	12/365,883	  	February 4, 2009
				
	109	  	Quinazoline derivatives and methods of treatment	  		  	
		  	 China (People’s Republic)
	  	200980118829.90	  	March 27, 2009
		  	 Korea, Republic of
	  	10-2010-7024204	  	March 27, 2009
		  	 Japan
	  	2011-502126	  	March 27, 2009
		  	 Hong Kong
	  	11108819.9	  	March 27, 2009
				
	110	  	4-aminoquinazoline prodrugs	  		  	
		  	 United States of America
	  	12/986,135	  	January 6, 2011

  
 Page 15 of 16

							
	 	  	Title	  	Application Number	  	Filing Date
				
	111	  	Deuterated macrocyclic inhibitors of viral NS3 protease	  		  	
		  	 United States of America
	  	13/092,801	  	April 22, 2011
				
	112	  	Substituted triazolophthalazine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/045508	  	August 13, 2010
		  	 United States of America
	  	12/856,360	  	August 13, 2010
				
	113	  	Substituted benzimidazoles	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/052915	  	October 15, 2010
		  	 United States of America
	  	12/905,835	  	October 15, 2010
				
	114	  	Substituted imidazotriazines	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/043097	  	July 23, 2010
		  	 United States of America
	  	12/842,589	  	July 23, 2010
				
	115	  	Substituted triazolo-pyridazine derivatives	  		  	
		  	 Patent Cooperation Treaty
	  	PCT/US2010/039497	  	June 22, 2010
		  	 United States of America
	  	12/820,570	  	June 22, 2010
				
	116	  	2-oxo-1-pyrrolidine derivatives	  		  	
		  	 United States of America
	  	13/002,267	  	June 30, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US09/49224	  	June 30, 2009
				
	117	  	Deuterated Tivozanib	  		  	
		  	 United States of America
	  	61/496,201	  	June 13, 2011
				
	118	  	Analogues of cilostazol	  		  	
		  	 United States of America
	  	12/150,107	  	April 24, 2008
		  	 United States of America
	  	12/644,758	  	December 22, 2009
		  	 EP
	  	8743256.3	  	November 25, 2009
		  	 Patent Cooperation Treaty
	  	PCT/US08/05301	  	April 24, 2008
				
	119	  	4-aminoquinazolines	  		  	
		  	 Australia
	  	2007288204	  	August 22, 2007
		  	 Canada
	  	2,661,223	  	August 22, 2007
		  	 United States of America
	  	12/879,905	  	September 10, 2010
		  	 China (People’s Republic)
	  	200780093901.3	  	August 22, 2007
		  	 European Union
	  	EP07811504.5	  	August 22, 2007
		  	 India
	  	423/MUMNP/2009	  	August 22, 2007
		  	 Japan
	  	2009-525631	  	August 22, 2007
		  	 Mexico
	  	MX/a/2009/001814	  	August 22, 2007
		  	 United States of America
	  	11/895,174	  	August 22, 2007
		  	 Patent Cooperation Treaty
	  	PCT/US2007/018655	  	August 22, 2007
		  	 Korea
	  	2009-0042994	  	August 22, 2007

  
 Page 16 of 16

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL
NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
	Argentina	  	CONCERT PHARMACEUTICALS INC.	  	2210582	  	01/29/2008	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/29/2018
						
	Australia	  	CONCERT PHARMACEUTICALS INC.	  	1157917	  	1/25/2007	  	A full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Australia	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	1157926	  	1/25/2007	  	A full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Canada	  	CONCERT PHARMACEUTICALS INC.	  	1,332,456	  	1/24/2007	  	A full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Pending
						
	Canada	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	1,332,461	  	1/24/2007	  	A full line of pharmaceutical and bio pharmaceutical preparations namely, pharmaceutical compounds for use in treating diseases and health conditions namely, pharmaceuticals for the
treatment of inflammatory diseases, infectious diseases, diseases and conditions of the central nervous system, cancer, and cardiovascular disease.	  	Pending
						
	China	  	CONCERT PHARMACEUTICALS INC.	  	5,868,162	  	3/7/2011	  	Medical nutriment	  	Registered, expires 3/6/2021
						
	China	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	5,868,163	  	3/7/2011	  	Medical nutriment	  	Registered, expires 3/6/2021

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL
NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
	European Community	  	CONCERT PHARMACEUTICALS INC.	  	5641204	  	1/30/2008	  	 Pharmaceutical and veterinary preparations; biopharmaceutical preparations; full line of pharmaceutical and biopharmaceutical
preparations in Class 5.
  
 Pharmaceutical research and development services
in Class 42.
	  	Registered, expires 1/25/2017
						
	European Community	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	5641295	  	1/23/2008	  	Pharmaceutical and veterinary preparations; biopharmaceutical preparations; full line of pharmaceutical and biopharmaceutical preparations in Class 5.	  	Registered, expires 1/25/2017
						
		  		  		  		  	Pharmaceutical research and development services in Class 42.	  	
						
	India	  	CONCERT PHARMACEUTICALS INC.	  	1526295	  	1/25/2007	  	Full line of pharmaceutical and biopharmaceutical preparations	  	Pending
						
	Israel	  	CONCERT PHARMACEUTICALS INC.	  	197279	  	5/10/2009	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Japan	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	5060415	  	7/6/2007	  	Pharmaceuticals in Class 5	  	Registered, expires 7/6/2017
						
	Japan	  	CONCERT PHARMACEUTICALS INC.	  	5060416	  	7/6/2007	  	Pharmaceuticals in Class 5	  	Registered, expires 7/6/2017

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL

NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
	New Zealand	  	CONCERT PHARMACEUTICALS INC.	  	762543	  	7/25/2006	  	Pharmaceutical and biopharmaceutical preparations but not including pharmaceutical preparations to treat hyperactivity and attention deficit disorder in children in Class
5	  	Registered, expires 7/25/2016
						
	Norway	  	CONCERT PHARMACEUTICALS INC.	  	239760	  	6/20/2007	  	Complete set of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 6/20/17
						
	Russian Federation	  	CONCERT PHARMACEUTICALS INC.	  	346050	  	3/20/2008	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Singapore	  	CONCERT PHARMACEUTICALS INC.	  	T07/017771	  	1/25/2007	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, Renewal due 1/25/2017
						
	South Africa	  	CONCERT PHARMACEUTICALS INC.	  	2007/01346	  	4/22/2010	  	Full line of pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Switzerland	  	CONCERT PHARMACEUTICALS INC.	  	559007	  	6/1/2007	  	Pharmaceutical and biopharmaceutical preparations in Class 5	  	Registered, expires 1/25/2017
						
	Taiwan	  	CONCERT PHARMACEUTICALS	  	1297040	  	1/16/2008	  	Western medicine, biological medicine preparations in Class 5	  	Registered, Renewal due 1/15/2018
						
	United States	  	CONCERT PHARMACEUTICALS INC.	  	78937102	  	7/25/2006	  	Prescription pharmaceutical and biopharmaceutical preparations, namely, pharmaceutical preparations for use in treating inflammatory diseases, infectious diseases, cancer and
cardiovascular disease in Class 5	  	Published

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL
NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
		  		  		  		  	Pharmaceutical research and development services in Class 42	  	
						
	United States	  	CONCERT PHARMACEUTICALS INC. (stylized)	  	78937142	  	7/25/2006	  	Prescription pharmaceutical and biopharmaceutical preparations, namely, pharmaceutical preparations for use in treating inflammatory diseases, infectious diseases, cancer and
cardiovascular disease in Class 5	  	Published
						
		  		  		  		  	Pharmaceutical research and development services in Class 42	  	

 Concert Pharmaceuticals, Inc. Trademarks 

 

											
	 COUNTRY
	  	 MARK
	  	 REG. NO./
SERIAL
NO.
	  	 ISSUED/
FILED
	  	 GOOD/SERVICES WITH CLASS
	  	 NOTES/ CURRENT STATUS

						
	United States	  	DCE PLATFORM	  	77907107	  	1/7/2010	  	Pharmaceutical compounds for clinical study use in drug research, namely, deuterium-based compounds for research use; chemical compounds for making and studying pharmaceutical
compounds, namely, deuterium-based compounds wherein each chemical compound contains one or more deuterium atoms for use in the manufacture of pharmaceutical preparations; pharmaceutical compounds for clinical study for research purposes and
laboratory use in drug research, namely, deuterium-based compounds in Class 1	  	Allowed
						
		  		  		  		  	Pharmaceutical compounds for use in treating diseases and health conditions, namely, pharmaceuticals for the treatment of treatment of inflammatory and fibrotic diseases, infectious
diseases, diseases and conditions of the central nervous system, cancer, and cardiovascular and renal disease; pharmaceutical compounds for clinical study for therapeutic purposes, namely, deuterium-based compounds in Class 5	  	
						
		  		  		  		  	Scientific and medical research services; medical testing services for research purposes; conducting early evaluations in the field of new pharmaceuticals; drug discovery services;
pharmaceutical research services in Class 42	  	

 EXHIBIT E 
 BORROWER’S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS 
  

							
	 Bank Name
	  	 Account Number
	  	 Branch Address
	  	 Company/Subsidiary

				
	Silicon Valley Bank	  	3300530507	  	3003 Tasman Drive Santa Clara, CA 95054	  	Company x OR Name of Sub
				
	Silicon Valley Bank	  	3300580848	  	3003 Tasman Drive Santa Clara, CA 95054	  	Company x OR Name of Sub
				
	State Street Bank	  	DE3085	  	1200 Crown Colony Drive Quincy, MA 02169	  	Company x OR Name of Sub
				
	 State Street Bank
  

Note: All cash/investments moved to DE3085. Concert requested on 12/9/11 that the DE3086 be closed.
	  	DE3086	  	1200 Crown Colony Drive Quincy, MA 02169	  	 Company  ̈ OR
 Name of Sub Concert Pharmaceuticals Securities Corporation

				
	SVB Securities	  	486-04255	  	3003 Tasman Drive Santa Clara, CA 95054	  	Company x OR Name of Sub
				
	SVB Securities	  	486-05241	  	3003 Tasman Drive Santa Clara, CA 95054	  	Company x OR Name of Sub

 EXHIBIT F 
 COMPLIANCE CERTIFICATE 
 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA
94301 
 Reference is made to that certain Loan and Security Agreement dated December     , 2011 and all
ancillary documents entered into in connection with such Loan and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”) between Hercules Technology Growth Capital, Inc.
(“Hercules”) as Lender and CONCERT PHARMACEUTICALS, INC. (the “Company”) as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement. 

The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification
of information regarding the Company; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period ending
                     of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true
and correct in all material respects on and as of the date of this Compliance Certificate. Attached are the required documents supporting the above certification. The undersigned further certifies on behalf of the Company that these are prepared in
accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect
to revenue recognition for upfront and milestone payments, and are consistent from one period to the next except as explained below. 
  

					
	REPORTING REQUIREMENT	  	REQUIRED	  	 CHECK
 IF ATTACHED

			
	Interim Financial Statements	  	Monthly within 30 days	  	
			
	Interim Financial Statements	  	Quarterly within 45 days	  	
			
	Audited Financial Statements	  	FYE within 180 days	  	

  

			
	Very Truly Yours,
	
	CONCERT PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Its:	 	  

 EXHIBIT G 
 FORM OF JOINDER AGREEMENT 
 This Joinder Agreement (the “Joinder
Agreement”) is made and dated as of                          , 201  , and is entered into by and between
                    , a                     
corporation (“Subsidiary”), and Hercules Technology Growth Capital, Inc. as a Lender. 
 RECITALS 

A. Subsidiary’s Affiliate, CONCERT PHARMACEUTICALS, INC. (“Company”) has entered into that certain Loan and
Security Agreement dated December     , 2011, with Lender, as such agreement may be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith; 

B. Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company’s execution of the Loan
Agreement and the other agreements executed and delivered in connection therewith; 
 AGREEMENT 

NOW THEREFORE, Subsidiary and Lender agree as follows: 
  

	1.	The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized terms not defined herein shall have the meaning provided in the
Loan Agreement. 

  

	2.	By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the
Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that Lender shall have no duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other agreements executed and
delivered in connection therewith. Rather, to the extent that Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith, those duties,
responsibilities or obligations shall flow only to Company and not to Subsidiary or any other person or entity. By way of example (and not an exclusive list): (a) Lender’s providing notice to Company in accordance with the Loan Agreement
or as otherwise agreed between Company and Lender shall be deemed provided to Subsidiary; (b) a Lender’s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (c) Subsidiary shall have no right to request an
Advance or make any other demand on Lender. 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 [SIGNATURE PAGE TO JOINDER AGREEMENT] 

 

			
	SUBSIDIARY:
	
	  

		
	By:	 	  

	Name:	 	  

	Title:	 	  

		
	Address:	 	  

		
	Telephone:	 	  

	Facsimile:	 	  

  

							
	LENDER:	 		 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Its:	 	  

 EXHIBIT H 
 ACH DEBIT AUTHORIZATION AGREEMENT 
 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA
94301 
 Re: Loan and Security Agreement dated December     , 2011 between CONCERT PHARMACEUTICALS, INC.
(“Borrower”) and Hercules Technology Growth Capital, Inc. (“Company”) (the “Agreement”) 
 In connection with the
above referenced Agreement, the Borrower hereby authorizes the Company to initiate debit entries for the periodic payments due under the Agreement to the Borrower’s account indicated below. The Borrower authorizes the depository institution
named below to debit to such account. 
  

			
	DEPOSITORY NAME	  	BRANCH
		
	CITY	  	STATE AND ZIP CODE
		
	TRANSIT/ABA NUMBER	  	ACCOUNT NUMBER

 This authority will remain in full force and effect so long as any amounts are due under the Agreement. 

 

			
	CONCERT PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Date:	 	  

 SCHEDULE 1 
 SUBSIDIARIES 
 Concert Pharmaceuticals Securities Corp., a Massachusetts corporation

 SCHEDULE 1A 
 EXISTING PERMITTED INDEBTEDNESS 
 None. 

 SCHEDULE 1B 
 EXISTING PERMITTED INVESTMENTS 
 Investment in Concert Pharmaceuticals Securities Corp.

 SCHEDULE 1C 
 EXISTING PERMITTED LIENS 
 None. 

 SCHEDULE 5.3 
 CONSENTS, ETC. 
 None. 

 SCHEDULE 5.5 
 ACTIONS BEFORE GOVERNMENTAL AUTHORITIES 
 None. 

 SCHEDULE 5.8 
 TAX MATTERS 
 None. 

 SCHEDULE 5.9 
 INTELLECTUAL PROPERTY CLAIMS 
 None. 

 SCHEDULE 5.10 
 INTELLECTUAL PROPERTY 
 None. 

 SCHEDULE 5.11 
 BORROWER PRODUCTS 
 None. 

 SCHEDULE 5.14 
 CAPITALIZATION 
 Borrower owns all of the outstanding capital stock of Concert
Pharmaceuticals Securities Corp. See attached capitalization table of Borrower. 

 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT 

THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (“Amendment”) is made and dated as of
January     , 2014, and is entered into by and between CONCERT PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation
(“Lender”). Capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Loan Agreement (defined below). 
 RECITALS 
 A. The Borrower and the Lender are party to that certain Loan
and Security Agreement dated as of December 22, 2011 (the “Loan Agreement”). 
 B. Each of the Borrower’s
audited financial statements delivered to the Lender under the Loan Agreement refer to certain liabilities of the Borrower to the landlord in connection with tenant improvements under the Borrower’s real estate lease. 

C. The parties desire to amend the Loan Agreement on the terms set forth herein to clarify that such liabilities to the landlord are
permitted under the terms of the Loan Agreement. 
 AGREEMENT 

NOW, THEREFORE, Borrower and Lender agree as follows: 
 1. Effective as of December 22, 2011, Schedule 1A of the Loan Agreement is hereby amended and replaced with Schedule 1A attached hereto as Annex A. 

2. The Lender waives any defaults or events of default arising from the items on Annex A not being included on Schedule 1.1 on the
Closing Date. 
 3. Except as modified herein, the Loan Agreement remains unchanged and in full force and effect. The Borrower
hereby ratifies, confirms and reaffirms the terms and conditions of the Loan Agreement and the Loan Documents, and all grants of security by the Borrower to the Lender in connection therewith. 

4. This Amendment shall be governed by, and construed and enforced in accordance with, the laws of the Commonwealth of Massachusetts,
excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 
 [Remainder of Page
Intentionally Blank] 

  
 1 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this First
Amendment to Loan and Security Agreement as of the day and year first above written. 
  

			
	BORROWER:
	
	CONCERT PHARMACEUTICALS, INC.
		
	Signature:	 	 /s/ Nancy Stuart

		
	Print Name:	 	 Nancy Stuart

		
	Title:	 	 Chief Operating Officer

 Accepted in Boston, Massachusetts: 

 

					
	LENDER:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	 /s/ Ben Bang

	Name:	 	 Ben Bang

	Its:	 	 Senior Council

  
 2 

 Annex A 
 Schedule 1A 
 EXISTING PERMITTED INDEBTEDNESS 

Pursuant to the Borrower’s real estate lease with One Ledgemont LLC with respect to the lease of the Borrower’s headquarters in
Lexington, Massachusetts in the building known as Ledgemont Development Center, and as more fully described in the Borrower’s audited financial statements for fiscal year end 2008 and subsequent years, the Borrower is obligated to reimburse the
landlord for certain leasehold improvement costs, in the original amount of $2.3 million plus interest. 

 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT 

THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (“Amendment”) is made and dated as of August 11, 2014, and is entered
into by and between CONCERT PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”). Capitalized terms used herein without
definition shall have the meanings ascribed to such terms in the Loan Agreement (defined below). 
 RECITALS 

A. The Borrower and the Lender are party to that certain Loan and Security Agreement dated as of December 22, 2011, as amended as of
January 14, 2014 (the “Loan Agreement”). 
 B. The parties desire to amend the Loan Agreement on the terms set
forth herein. 
 AGREEMENT 
 NOW, THEREFORE, Borrower and Lender agree as follows: 
 1. Section 7.1(c) of
the Loan Agreement is hereby amended and restated as follows: 
 (c) as soon as practicable and in any event within ninety days
(90 days) after the end of each fiscal year, audited financial statements as of the end of such year (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in
comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Lender, accompanied by an audit report from such accountants
which is unqualified as to scope of audit; 
 2. Section 7.1 of the Loan Agreement is hereby amended by deleting the final
paragraph thereof, and replacing it with the following: 
 “The executed Compliance Certificate may be sent to Lender via
e-mail to jbourque @herculestech.com. All Financial Statements required to be delivered pursuant to clauses (a), (b) and (c) shall be sent via e-mail to financialstatements@herculestech.com with a copy to jbourque@herculestech.com provided
that, (i) if e-mail is not available or sending such Financial Statements via e-mail is not possible, they may be sent via facsimile to Lender at: (866) 468-8916, attention Chief Credit Officer, and (ii) documents to be furnished
under Sections 7.1(b) and (c) may be furnished as set forth in the following sentence. Documents required to be delivered under Sections 7.1(b), (c) and (e) shall be deemed properly delivered on the date on which the Borrower posts
such documents, or provides a link thereto on the Borrower’s website, or the date on which such documents are available on Edgar or other publicly available website and Borrower notifies Lender by email of such availability.” 

 3. The Compliance Certificate is hereby amended by deleting “180 days” and
replacing it with “90 days.” 
 4. Except as modified herein, the Loan Agreement remains unchanged and in full force
and effect. The Borrower hereby ratifies, confirms and reaffirms the terms and conditions of the Loan Agreement and the Loan Documents, and all grants of security by the Borrower to the Lender in connection therewith. 

5. This Amendments shall be governed by, and construed and enforced in accordance with, the laws of the Commonwealth of Massachusetts,
excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 
 6. The Borrower
represents that no Event of Default has occurred and is continuing. 
 [Remainder of Page Intentionally Blank] 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this First
Amendment to Loan and Security Agreement as of the day and year first above written. 
  

			
	 BORROWER:
  

CONCERT PHARMACEUTICALS, INC.

		
	Signature:	 	/s/ Ryan Daws
		
	Print Name:	 	Ryan Daws
		
	Title:	 	Chief Financial Officer

 Accepted in Boston, Massachusetts: 

 

			
	 LENDER:
  

HERCULES TECHNOLOGY
 GROWTH CAPITAL,
INC.

		
	By:	 	/s/ Ben Bang
		
	Name:	 	Ben Bang
		
	Its:	 	Senior Council

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]